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Abstract
A randomised controlled trial of the probiotic
Bifidobacterium breve BBG-001 in preterm babies to prevent
sepsis, necrotising enterocolitis and death: the Probiotics in
Preterm infantS (PiPS) trial
Kate Costeloe,1,2* Ursula Bowler,3 Peter Brocklehurst,3,4
Pollyanna Hardy,3 Paul Heal,3 Edmund Juszczak,3 Andy King,3
Nicola Panton,1 Fiona Stacey,1,2 Angela Whiley,1 Mark Wilks1,5
and Michael R Millar1,5
1Barts and the London School of Medicine and Dentistry, Queen Mary University of London,
London, UK
2Homerton University Hospital NHS Foundation Trust, London, UK
3National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK
4Institute for Women’s Health, University College London, London, UK
5Barts Health NHS Trust, London, UK
*Corresponding author k.l.costeloe@qmul.ac.uk
Background: Necrotising enterocolitis (NEC) and late-onset sepsis remain important causes of death
and morbidity in preterm babies. Probiotic administration might strengthen intestinal barrier function
and provide protection; this is supported by published meta-analyses, but there is a lack of large
well-designed trials.
Objective: To test the use of the probiotic Bifidobacterium breve strain BBG-001 to prevent NEC,
late-onset sepsis and death in preterm babies while monitoring probiotic colonisation of participants.
Design: Double-blind, randomised, placebo-controlled trial.
Setting: Recruitment was carried out in 24 hospitals, and the randomisation programme used a
minimisation algorithm. Parents, clinicians and outcome assessors were blinded to the allocation.
Participants: Babies born between 23 and 30 weeks’ gestation and randomised within 48 hours of birth.
Exclusions included life-threatening or any gastrointestinal malformation detected within 48 hours
of birth and no realistic chance of survival.
Interventions: Active intervention: 1 ml of B. breve BBG-001 in one-eighth-strength infant formula
Neocate® (Nutricia Ltd, Trowbridge, UK), (6.7 × 107 to 6.7 × 109 colony-forming units) per dose
administered enterally. Placebo: 1 ml of one-eighth-strength infant formula Neocate. Started as soon as
practicable and continued daily until 36 weeks’ postmenstrual age.
Main outcome measures: Primary outcomes were an episode of bloodstream infection, with any
organism other than a skin commensal, in any baby between 72 hours and 46 weeks’ postmenstrual age;
an episode of NEC Bell stage ≥ 2 in any baby; and death before discharge from hospital. Secondary
outcomes included stool colonisation with B. breve.
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Results: In total, 654 babies were allocated to receive probiotic and 661 to receive placebo over 37 months
from July 2010. Five babies were withdrawn; 650 babies from the probiotic group and 660 from the
placebo group were included in the primary analysis. Baseline characteristics were well balanced. There was
no evidence of benefit for the primary outcomes {sepsis: 11.2% vs. 11.7% [adjusted relative risk (RR) 0.97,
95% confidence interval (CI) 0.73 to 1.29]; NEC Bell stage ≥ 2: 9.4% vs. 10.0% [adjusted RR 0.93,
95% CI 0.68 to 1.27]; and death: 8.3% vs. 8.5% [adjusted RR 0.93, 95% CI 0.67 to 1.30]}. B. breve
colonisation status was available for 1186 (94%) survivors at 2 weeks’ postnatal age, of whom 724 (61%)
were positive: 85% of the probiotic group and 37% of the placebo group. There were no differences
for subgroup analyses by minimisation criteria and by stool colonisation with B. breve at 2 weeks.
No harms associated with the interventions were reported.
Limitations: Cross-colonisation of the placebo arm could have reduced statistical power and confounded
results; analyses suggest that this did not happen.
Conclusions: This is the largest trial to date of a probiotic intervention. It shows no evidence of benefit
and does not support routine use of probiotics for preterm infants.
Future work recommendations: The increasing understanding of the pathogenesis of NEC and sepsis
will inform the choice of probiotics for testing and better define the target population. Future Phase III
trials should incorporate monitoring of the quality and viability of the intervention and colonisation rates
of participants; cluster design should be considered.
Trial registration: Current Controlled Trials ISRCTN05511098 and EudraCT 2006-003445-17.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 66.
See the NIHR Journals Library website for further project information.
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Plain English summary
Infection contracted after birth and necrotising enterocolitis (NEC), which is the most common seriouscomplication affecting the gut, are important causes of death and life-long health problems for
premature babies. It is thought that giving ‘good bacteria’ (probiotics) might strengthen the bowel wall
and provide protection by preventing bacteria that cause disease from entering the body.
Previous trials of probiotics have provided encouragement, particularly when the results of different trials
are added together, but there are concerns about the reliability of some of the trials.
This trial aimed to overcome problems of earlier trials, in particular by being big enough to give
clear answers.
The trial was successfully completed and results are available for 1310 babies, born more than 9 weeks
early, in 24 different hospitals; 650 were allocated to receive probiotics.
No problem was reported with safety but neither was there any evidence of benefit associated with giving
this probiotic to these babies in preventing NEC, severe infection, death or any of the other common
problems of prematurity.
We believe that our results support the view that different types of probiotic may have different effects
and that it may be a mistake to combine the results of trials of different probiotics as if they were all the
same. Although short-term safety is good, we do not yet know about longer-term effects of these
products on child development or illnesses such as asthma and, until we know more, we should be
cautious about their use.
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Scientific summary
Background
Necrotising enterocolitis (NEC) and late-onset sepsis remain important causes of mortality and morbidity in
the preterm infant. The postnatal acquisition of diverse bowel flora is delayed in the preterm infant; this
may contribute to reduced barrier properties of the intestinal mucosa, making invasion and/or translocation
of the bowel wall by potentially pathogenic bacteria more likely. The hypothesis underpinning studies of
probiotic administration in preterm babies is that, by encouraging the bowel flora to resemble that of a
healthy breast-fed full-term infant more closely, barrier function will be improved and the incidence
of late-onset sepsis and NEC will be reduced. The most recent Cochrane review of this topic includes
20 randomised trials with > 5500 participants. The meta-analysis suggests that probiotics do not reduce
sepsis but are associated with statistically significant reductions in NEC incidence and all-cause mortality;
no adverse events were reported in any trial and the recommendation was made that probiotics should be
given routinely to preterm infants, including those whose birthweight is < 1 kg. Despite this, the use of
probiotics is variable. Concern has been expressed about the rigour of a number of the published trials, the
heterogeneity of the participants, particularly in respect of exclusions and rates of NEC and death in the
placebo groups, and the wide range of interventions. These live microbial products are likely to cross-
colonise babies, yet none of the trials systematically reports stool colonisation by the administered strains in
either the active intervention or placebo groups. This leaves clinicians uncertain about the benefit of
routine use and with little guidance as to choice of product.
Objective
To evaluate efficacy and safety of Bifidobacterium breve strain BBG-001 to reduce NEC incidences,
late-onset sepsis and death in an unselected population of preterm infants in England.
Design
Double-blind, placebo-controlled trial.
Setting
Hospitals with tertiary or secondary neonatal intensive care units in and around London. Recruitment
took place in 24 hospitals and continuing care prior to the initial discharge from hospital in a further
33 hospitals.
Participants
Babies born between 23+0 and 30+6 weeks’ gestation were randomised within 48 hours of birth.
The randomisation program used a minimisation algorithm to ensure balance on hospital, sex, gestational
age and whether or not randomisation occurred within 24 hours of birth. Multiple births were randomised
individually. Those with potentially lethal malformations or any gastrointestinal malformation apparent
within 48 hours of birth or no realistic chance of survival were excluded.
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Interventions
The active intervention, B. breve BBG-001, was provided in single-dose sachets as a powder, freeze-dried
with maize starch. The placebo was maize starch alone provided as an identical powder in identical
sachets. The interventions were suspended in 3ml of one-eighth strength of the ‘elemental’ formula
Neocate® (Nutricia Ltd, Trowbridge, UK), the maize starch allowed to settle and 1ml of the supernatant,
estimated to contain 6.7 × 107 to 6.7 × 109 colony-forming units of B. breve BBG-001, administered daily.
The interventions were started as soon as practicable after randomisation, whether or not enteral feeding
had begun, and were continued until 36 weeks’ postmenstrual age.
Feeding and clinical care including withholding of the intervention was at the discretion of local clinicians.
Stools at 14 days’ postnatal and 36 weeks’ postmenstrual age were cultured for B. breve using a selective
medium provided by the manufacturer. If enough stool was available, the 14-day sample was additionally
analysed using a strain-specific quantitative real-time polymerase chain reaction.
Main outcome measures
Primary outcomes
1. Any baby with an episode of bloodstream infection, with any organism other than a skin commensal,
more than 72 hours after birth and before 46 weeks’ postmenstrual age.
2. Any baby with an episode of NEC Bell stage ≥ 2.
3. Death before discharge from hospital.
Secondary outcomes
Secondary outcomes included the composite of the primary outcomes, a range of microbiological
outcomes including antimicrobial usage and stool colonisation with B. breve and antibiotic-resistant
pathogens, time to full enteral feeding, weight gain to 36 weeks’ postmenstrual age and major
neonatal morbidities.
Statistical power
At a two-sided significance level of 5%, a trial of 1300 infants would have 90% power to detect a 40%
relative risk (RR) reduction from 15% to 9.1% for each of the primary outcomes. If the outcomes were less
frequent, then the trial would have 90% power to detect a 44% RR reduction from 12% to 6.7% or from
10% to 5.6%.
Results
Recruitment continued for 37 months from July 2010; 654 babies were allocated to receive probiotic and
661 placebo. Consent to use data was withdrawn for five babies, and 650 infants in the probiotic group
and 660 in the placebo group were included in the intention-to-treat analysis.
Baseline characteristics were well balanced: the overall median gestation age was 28 weeks (48%
< 28 weeks); the median birthweight was 1010 g (49%< 1000 g); 91% were exposed to antenatal
corticosteroid; 36% were exposed to maternal antibiotics within 24 hours of birth; 53% were delivered by
caesarean section; 25% were recruited in the first 24 hours after birth; and the intervention was started at
a median age of 44 hours. At 14 days, 96% of those infants who were still alive had received some
maternal breast milk, augmented in 48.5% with either donor breast or formula milk.
SCIENTIFIC SUMMARY
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All comparative analyses were adjusted for sex, gestational age and randomisation within 24 hours of
birth. Allowance was made for correlations between multiple births. The primary analysis by intention to
treat showed no evidence of benefit for any of the primary outcomes {sepsis: 11.2% vs. 11.7% [adjusted
RR 0.97, 95% confidence interval (CI) 0.73 to 1.29]; NEC Bell stage ≥ 2: 9.4% vs. 10.0% [adjusted
RR 0.93, 95% CI 0.68 to 1.27]; and death: 8.3% vs. 8.5% [adjusted RR 0.93, 95% CI 0.67 to 1.30]}.
Of those surviving at 2 weeks’ postnatal age, B. breve colonisation status was available for 1186 (94%).
In total, 724 (61%) infants were positive: 85% of the active intervention group and 37% of the
placebo group.
Subgroup analyses by colonisation status, sex, gestational age as per minimisation, birthweight (≥1000 or
< 1000 g), birth (< 28 weeks’ gestational age or ≥ 28 weeks’ gestational age) and randomisation within
24 hours of birth suggested reduced sepsis rates in those born at 28 or 29 weeks [odds ratio (OR) 0.39,
95% CI 0.16 to 0.96], but no other differences for any of the primary outcomes.
Secondary outcomes
There were no differences between the groups for secondary outcomes (apart from B. breve colonisation)
including the composite outcome of late-onset sepsis, NEC or death. One or both of the stool sampless
collected from 38 out of 611 (6.2%) infants in the probiotic group and 35 out of 619 (5.7%) in the
placebo group were colonised with antibiotic-resistant bacteria.
In the probiotic group, colonisation was more likely with each week of increasing gestation (OR 1.36;
p< 0.0001) and less likely in those given any antibiotic between days 6 and 14 (OR 0.26; p= 0.0027).
In a secondary non-random analysis, among those with B. breve colonisation status known at 2 weeks,
there were trends towards fewer babies with primary outcomes associated with colonisation, but none of
the findings was statistically significant.
The interventions were well tolerated; there were no positive cultures of B. breve from any normally sterile
site and no adverse events related to the interventions were reported.
Throughout the recruitment period, the number of viable organisms in the intervention declined slowly,
but remained in the expected range and no contaminants were detected.
Conclusions
We believe that the population recruited into this trial is representative of the total population in this
geographic area at risk of NEC and late-onset sepsis. It is the first completed trial performed in accordance
with the International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use – Good Clinical Practice standard and to have systematically studied stool
colonisation in all trial centres. The trial has adequate statistical power and the use of a product containing
a single bacterial strain provides a clear result.
Although confirming the short-term safety of probiotic interventions, this trial provides no evidence that
this particular product is associated with advantage in this population of babies. This result supports the
view that it is necessary to assess the efficacy of different probiotic strains in different clinical situations and
challenges the validity of combining trials using different probiotic interventions in meta-analyses.
Implications for clinical practice
The results of this trial provide no evidence that supplementation with B. breve BBG-001 would affect the
risk of late-onset sepsis, NEC or death in this population.
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Implications for research
We find no evidence that further trials should be undertaken of this probiotic in this population.
The results of this trial have implications for the design of trials of other probiotic interventions:
l Colonisation rates of both the active and placebo groups should be monitored throughout the trial.
l Cluster design should be considered to reduce any confounding effects of cross-colonisation.
Future work recommendations
The increasing understanding of the pathogenesis of NEC and late-onset sepsis will inform the choice of
probiotics for testing and better define the target population. Future Phase III trials should incorporate
monitoring of the quality and viability of the intervention and colonisation rates of participants;
cluster design should be considered.
Trial registration
This trial is registered as ISRCTN05511098 and EudraCT 2006-003445-17.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
This is a multicentre, double-blind, randomised, placebo-controlled trial to study possible benefits of theearly administration of the probiotic Bifidobacterium breve strain BBG-001 to babies born before
31 weeks’ gestation and recruited within 48 hours of birth. The primary end points are late-onset
bloodstream infection diagnosed on a sample drawn after 72 hours, necrotising enterocolitis (NEC) and
death. The trial aimed to recruit 1300 babies from approximately 20 UK neonatal units.
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Chapter 2 Scientific background
Acquired infection and necrotising enterocolitis in
preterm babies
Hospital-acquired infection is reported in about 25% of babies with birthweight < 1500 g who survive the
first 3 days,1 and it contributes to the high mortality and morbidity in this population.
Necrotising enterocolitis is the most common serious gastrointestinal complication of preterm birth and has
high mortality and morbidity.2,3 The pathogenesis of NEC is multifactorial,4 related to immaturity of the
immunological and barrier functions and involving bacterial invasion of the intestinal mucosa. There is no
agreed international diagnostic case definition for NEC; the system most widely used is the ‘modified’ Bell
classification,5 which involves a range of clinical, haematological and radiological criteria. Bell stage 1 is very
non-specific, whereas Bell stages 2 and 3 have more objective radiological features and are often considered
interchangeable with the terms ‘proven, confirmed or serious’ NEC used in some publications. Estimates of
the incidence of ‘confirmed’ NEC in babies with a birthweight of < 1500 g vary between about 6% and 10%.
The microbiome in the newborn baby and its relation to
late-onset sepsis and necrotising enterocolitis
The microbiome is the term used to describe the population of micro-organisms with which individual
humans co-exist, predominantly within the bowel. Healthy breastfed term infants become colonised early
in life with a wide range of bacteria dominated by bifidobacteria and lactobacilli acquired during and after
birth from close contact with the mother;6 these microbes are believed to confer a range of health
benefits. By comparison, preterm infants nursed in neonatal units become colonised with a more limited
range of bacteria and fungi.7–9 The pattern of colonisation reflects the micro-organisms found in the
‘antibiotic-rich’ environment of the neonatal unit and is dominated by members of the Enterobacteriaceae
family, Pseudomonas, enterococci, yeasts, staphylococci and clostridia that are potentially pathogenic and
may cause infection in the colonised infant or may spread and cause disease in other infants.
The specific mechanisms by which anaerobic lactobacilli and bifidobacteria protect against infection
with pathogenic organisms are believed to involve increased secretion of immunoglobulin A and
upregulation of immunoglobulin A receptor sites, strengthening of epithelial tight junctions, lowering
the intraluminal pH through acid fermentation and modification of intestinal inflammatory responses
through preferential stimulation of T-helper cells, all resulting in reduced bacterial translocation.10
This subject has been the focus of a number of reviews.11–13
The extent to which abnormal patterns of early colonisation of the intestine have deleterious effects on
later health is also incompletely understood. A number of recent studies have shown changes in the
patterns of stool bacterial colonisation in the period preceding the clinical onset of NEC and late-onset
sepsis,14–17 but whether or not these changes are causative or part of the disease process is unclear.
For the context of this trial a probiotic is defined as a live microbial supplement that colonises the gut and
improves health.18
The extent to which intestinal colonisation with probiotic bacteria can be achieved in the preterm newborn
baby is unclear. However, the concept of active management of the bowel flora to prevent hospital-acquired
infection and NEC is an attractive therapeutic option that seems likely to have a good safety profile.
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Probiotics and the prevention of late-onset sepsis and
necrotising enterocolitis
Randomised controlled trials
When the Probiotics in Preterm infantS (PiPS) trial was designed, we believed that only one randomised
controlled trial (RCT) had been published that reported the effect of probiotics on late-onset sepsis and/or
NEC in preterm babies. This was an Italian trial published in 2002 and involving 585 babies below
33 weeks’ gestational age19 treated with a product containing Lactobacillus rhamnosus GG. It failed to
show a significant reduction in NEC incidence or blood culture-positive episodes of late-onset sepsis
(probiotic vs. placebo: NEC, 1.4% vs. 2.7%; septic episodes, 4.1% vs. 4.7%). The results are difficult to
interpret, as the analysis was not by intention to treat; babies dying in the first 2 weeks were excluded and
only septic episodes and episodes of NEC with onset at least 7 days after commencement of the
intervention were considered in the analysis. This probably accounts for the low reported rates of
adverse outcomes.
When recruitment to the PiPS trial began in 2010, four20–23 further trials with clinical primary outcomes had
been published.
The first two trials were reported in 2005 and showed a reduction in the incidence of NEC in infants given
probiotic mixtures; both studies recruited at a single site. The first was from a hospital in Taiwan,20 in
which a mixture of L. acidophilus and B. infantis or placebo was given in breast milk twice daily until
discharge from hospital to 367 babies of birthweight < 1500 g, who had survived beyond 7 days and were
clinically stable with umbilical lines removed and commencing milk feeds. Reductions in incidence were
seen for NEC, from 5.3% to 1.1% (p= 0.04); blood culture-positive late-onset sepsis, from 19.3% to
12.2% (p= 0.03); death, from 10.7% to 3.9% (p= 0.009); and for the combined outcome of NEC,
late-onset sepsis or death from 32.1% to 17.2% (p= 0.009). The second study21 recruited 145 babies at
an Israeli hospital, who were randomised to receive a product containing three probiotic strains (B. infantis,
Streptococcus thermophilus and B. bifidus) or unsupplemented milk feeds given once a day. The median
age at commencement of the intervention was 3 days and the intervention was continued until
36 weeks’ postmenstrual age. There was no difference in episodes of blood culture-positive infection or of
death, but episodes of NEC appeared to be reduced in the intervention arm (16.4% vs. 4.0%; p= 0.03)
and it was reported that there was a reduction in the severity of the illness. These two studies, the first to
report prevention of NEC, were subject to considerable interest and extensive review.24–26
In 2007 a meta-analysis27 was published including these three trials19–21 together with four others designed
to study different outcomes, one of which involved a fungal rather than a bacterial intervention.28 A total
of 1393 babies were involved, and the conclusion was that there was evidence that probiotic interventions
might reduce the incidence of NEC and all-cause mortality, apparently without adverse effects, but that
there were important outstanding questions about choice of probiotic product and dosing.
The third and fourth RCTs with clinical primary outcomes were published in 2008 and 2009, a single-site
trial from a hospital in India22 and a multicentre trial from Taiwan.23 In the trial from India, a combination of
B. infantis, B. bifidum, B. longum and L. acidophilus given with breast milk twice daily to 186 babies of
< 32 weeks’ gestation and birthweight < 1500 g was compared with breast milk alone. Participants were
clinically stable and, as in the previous studies, receiving milk feeds. The end points included feed tolerance,
length of stay and serious neonatal morbidities. Babies dying from causes other than late-onset sepsis or
NEC were excluded and no power calculation was given. A significant reduction in time to achieve full feeds
and length of stay was reported to be associated with probiotic use. There was an overall reduction in all
stages of NEC from 15.8% in the control group to 5.5% in the probiotic group (p= 0.04), but no significant
reduction in the incidence of NEC of Bell stage ≥ 2. There was a significant reduction in culture-positive
late-onset sepsis, from 29.5% to 14.3% (p= 0.02), and of death, from 14.7% to 4.4% (p= 0.04).
SCIENTIFIC BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
The multicentre trial from Taiwan23 recruited a total of 434 babies of birthweight < 1500 g and gestational
age < 4 weeks from seven centres. A product containing B. bifidum and L. acidophilus was added to
the milk feed; babies entirely fed with formula were excluded, as were babies in whom feeds had not
been started by 3 weeks of age. There was a composite primary outcome, death or NEC Bell stage ≥ 2,
which was significantly lower in the intervention group (1.8% vs. 9.2%; p= 0.002). In addition, there were
more babies with late-onset sepsis in the intervention group (18.4% vs. 11.1%.) A large number of
infants died (98 out of a potential 580 eligible infants) without ever achieving the study entry criteria.
In the period leading up to the start of recruitment to the PiPS trial in 2010 and during recruitment there
have been sharp divisions in the paediatric literature about the use of probiotics. Some authors have
strongly advocated a change of practice to routine use29 because of the apparent association with a
reduction in NEC and death, as suggested in a series of meta-analyses,30–32 whereas others have
recommended caution because of the heterogeneity of the participants and of the interventions and the
methodological failings of some trials.33,34
At the time of writing, 11 RCTs designed to study the efficacy of a bacterial probiotic intervention,
with late-onset sepsis and/or NEC and/or death as the primary outcome, have been published in English.
These trials account for 4396 of the 5529 (80%) babies randomised in 20 trials included in the most
recent Cochrane review of probiotics to prevent NEC in preterm babies.35 These trials are characterised
by a range of inclusion and exclusion criteria and by varying exposure to maternal breast milk. This may,
in part, explain the wide reported ranges of rates of late-onset sepsis, NEC and death. Of those studies
reporting such data, mortality and NEC rates among excluded infants are in some cases high (Table 1).
The extent to which reviews such as this may be subject to publication bias is difficult to assess owing to the
inclusion of a large number of trials. Many of which are small and not designed to study clinical outcomes.
With the exception of a multicentre trial published in 2012 and recruiting babies of birthweight up to
2000 g,39 the probiotic intervention was given either in milk or, in one study,42 separately but coincident
with the start of feeding. This suggests that babies with perceived contraindications to starting feeds, who
are likely to be those babies at highest risk of NEC, might be excluded or have deferred entry to the trials.
The majority of the trials were not placebo controlled and relied on the responsible clinical staff being blind
to the allocation through the use of unsupplemented milk as the comparator (see Table 1).
None of the trials was designed with statistical power to study NEC or death rates as separate outcomes.
In contrast to NEC and death, the various meta-analyses do not suggest a protective effect of probiotics
for late-onset sepsis. The assessment of efficacy to reduce late-onset sepsis is complicated by the lack of a
standardised definition of the outcome.
This problem was addressed by the multicentre Australasian ProPrems trial,41 which is the largest of the
previously published trials. The results were presented in 2012 but were not published until after the
completion of PiPS trial recruitment. A rigorous definition of late-onset sepsis was used and the trial was
statistically powered to show a reduction from 23% to 16%. The event rates of both late-onset sepsis and
NEC in this trial were lower than predicted and a non-statistically significant reduction in late-onset sepsis,
from 16.2% to 13.1%, was observed.
It is generally held that, in order for a probiotic intervention to be effective, it should ‘colonise’ the intestine
and the administered bacteria should multiply within it. Successful colonisation is likely to be influenced by
local factors such as feeding and antimicrobial use. Human breast milk contains oligosaccharides known to
promote colonisation by bifidobacteria while many probiotic strains are sensitive to commonly administered
antimicrobials, for example bifidobacteria are sensitive to penicillins. Manufacturers of probiotics inevitably
select strains that readily colonise the intestine and, theoretically, these strains might be particularly likely to
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spread between babies, especially in hospitals where cots are close together or the nurse-to-baby ratio is
low. In this respect, the efficacy of a probiotic intervention might be expected to vary more between
different institutions than a standard chemical drug intervention. Of the 20 RCTs included in the most
recent Cochrane review,35 the only trial to report colonisation by allocated group in detail is the single-site
study reported by Kitajima et al.,43 which involved the administration of a single-strain probiotic product
containing B. breve YIT4010 (BBG-001). Of 45 babies in the probiotic group, 73% were colonised at
2 weeks and 91% at 6 weeks, whereas, of the 46 babies given placebo, 12% were colonised at 2 weeks
and 44% at 6 weeks. This adds a level of complexity to the interpretation of all data from trials of
probiotics, particularly for those using polymicrobial products, as it is likely that different components
will colonise babies in both groups so that at different time points in their clinical course babies might be
colonised with anywhere between none or all of the administered strains.
Observational studies/historic comparisons
Despite the frequent calls for probiotics to be used routinely for preterm babies, there are few published
accounts of their impact in routine use.
An early report44 of a trial in a tertiary hospital in Colombia, in which a product containing L. acidophilus
and B. infantis was given for 1 year to all admitted newborn infants, reported a decrease in all stages of
NEC compared with the previous year, from 6.6% (n= 1237) to 3.0% (n= 1282); all other aspects of care
were unchanged.
There have been more recent reports of use targeted towards preterm babies.
In 2010 Luoto et al.,45 reported on 12 years’ experience in five tertiary neonatal units in Finland. In one
neonatal unit, following an outbreak of NEC, administration of Lactobacillus GG was introduced for all
babies of birthweight < 1500 g. In three other neonatal units, the same product was administered to
babies with gastrointestinal problems and the final neonatal unit used no probiotic. The standard of care in
all hospitals was to use donor breast milk in the absence of maternal milk. The authors did not find a
protective effect in the hospital using ‘prophylactic’ probiotics when the incidence remained higher than in
the other hospitals or any effect on the clinical course of NEC in those hospitals in which probiotics were
given to symptomatic babies.
A further three retrospective cohort studies have been published.46–48
A report from a single site in the USA46 compared the incidence of NEC in 79 babies (of birthweight
≤ 1000 g) born between 2009 and 2011 in whom L. reuteri was routinely administered and babies born in
the previous 5 years; detailed feeding data were not reported and infants who died in the first week were
excluded. A reduction in NEC Bell stage ≥ 2 from 15.1% to 2.5% was reported (p= 0.0475); there were
baseline differences in the characteristics of the babies and between-year variation in NEC incidence.
In a study in France,47 during a 3-year period from 2008, babies born between 24 and 31 weeks’ gestation
(n= 347) and starting feeds within 48 hours of birth on a tertiary neonatal unit were administered
L. casei rhamnosus, Lcr35 strain from the beginning of feeding, their outcomes were compared with those
of unsupplemented babies born in the previous 5 years (n= 783). Babies dying in the first week were
excluded from the analysis.47 In the second period, the incidence of late-onset sepsis was reduced from
16.6% to 10.7% [odds ratio (OR) 0.60, 95% confidence interval (CI) 0.40 to 0.89], the incidence of NEC
Bell stage ≥ 2 was reduced from 5.3% to 1.2% (OR 0.23, 95% CI 0.08 to 0.69) and the mortality rate fell
from 4.8% to 2.3% (OR 0.46, 95% CI 0.21 to 1.00).
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A Canadian study48 published in 2014 reported NEC Bell stage ≥ 2 and the composite outcome NEC
or death of babies born before 32 weeks’ gestation for 17-month periods before (n= 317) and after
(n= 294) the introduction of a product containing B. breve, B. longum, B. bifidum, B. infantis and
Lactobacillus GG was given with the first feed at a single site. The incidence of NEC decreased from 9.8%
to 5.5% (p< 0.02) and the incidence of death or NEC fell from 17.0% to 10.5% (p< 0.05). There was a
non-significant reduction in death as a separate outcome. After adjustment for gestational age,
intrauterine growth restriction and sex, the OR for NEC in the second period was 0.51 (95% CI 0.26 to
0.98) and for death or NEC was 0.56 (95% CI 0.33 to 0.93).
Safety
None of the published RCTs or non-randomised studies, including a summary of 6 years’ use of
Lactobacillus GG across two neonatal units in northern Italy49 that contains no efficacy data, reports any
complications of probiotic administration; most importantly, no instances were recorded of late-onset
sepsis with the administered probiotic strains.
Before the beginning of recruitment to this trial there had been occasional reports, including in the
paediatric literature,50,51 of disseminated infection following enteral supplementation with Lactobacillus
species, but no reports of late-onset sepsis with Bifidobacterium. In 2010, what we believe to be the first
case of a Bifidobacterium septicaemia was reported.52 This involved a positive blood culture for B. breve
strain BBG-001 (the strain used for the PiPS trial) in a full-term baby recovering after surgery for
exomphalos. The baby is described as having a mild illness that was treated with standard empirical
antibiotic treatment involving ampicillin/sulbactam and amikacin; the child made an uneventful recovery.
In 2012, a second report53 described a twin born at 27 weeks’ gestation, birthweight 600 g, who was fed
with maternal breast and in whom a probiotic preparation containing B. infantis and L. acidophilus was
instituted on day 8. On day 18 the infant became unwell with abdominal symptoms. A blood culture grew
two species, B. infantis and B. longum. She was treated with vancomycin, cefotaxime and metronidazole,
and recovered.
There is an anxiety that, theoretically, manipulating the developing microbiome by administering probiotics
might modify the immunological function of the intestine or that antibiotic resistance genes might be
transferred from the probiotic to pathogenic bacteria, thereby putting the individual at increased
short-term risk of infection or possibly of unpredictable long-term health change.54
Studies on the effect of probiotics on intestinal colonisation with potential pathogens are few, and the
results inconsistent. A small study involving 30 babies, with a mean gestational age of 33 weeks and a mean
birthweight of 1486 g, was suggestive that B. breve administration might be associated with reduced
colonisation with Enterobacteriaceae.55 However, a more recent placebo-controlled randomised trial56 of
formula-fed babies, born before 32 weeks’ gestation, found increased colonisation with Enterobacteriaceae,
enterococci and staphylococci in 21 of 47 babies whose feed was supplemented with Lactobacillus GG. This
was not associated with increased late-onset sepsis in these babies. Of the 12 clinical trials listed in Table 1,
all of which were designed to study clinical outcomes, five reported higher rates of sepsis in the active arm
than in the placebo arm,19,21,23,37,39 although only one was statistically significant.23 These trials use various
definitions of late-onset sepsis.
A RCT studying a product with six bacterial strains, four species of Lactobacillus and two of Bifidobacterium,
in 296 adult patients with acute pancreatitis reported increased mortality in the active arm, [24/152 (16%)
vs. 9/144 (6%) in the placebo arm (p= 0.01)].57 The most frequent cause of death was multiorgan failure
and there were no reports of probiotic bacteraemias. In 9 of the 24 patients in the active group who died,
ischaemic bowel was found at either laparotomy or autopsy; ischaemic bowel was not found in those
patients in the placebo group who died. The intervention in this trial was given twice daily directly into the
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jejunum and represents a huge bacterial load, estimated at 1010 bacteria. The reasons for the increased
mortality are unclear. This trial might be interpreted as a reminder that, despite worldwide extensive
consumption of probiotics, it should not be assumed that they are safe in extremely ill patients with
compromised intestinal function; this would include preterm babies, particularly those with problems
establishing enteral nutrition.
The justification for continued recruitment to the PiPS trial was kept under review throughout its progress
as reports of more trials of routine use and of probiotic septicaemias became available; at no time was it
considered that the accumulating evidence either of efficacy or safety was such that a recommendation to
stop the trial early should be made. The overarching consideration was whether or not the findings of the
various trials were applicable to the population of preterm babies at risk of late-onset sepsis and NEC in
UK neonatal units. Rates of late-onset sepsis and NEC are inversely related to gestational age at birth2,58–60
and become relatively low from around 32 weeks’ gestation; the requirement of clinicians is for a
preventative intervention that can safely be given to all babies at risk of late-onset sepsis and NEC.
The choice of probiotic
The ideal probiotic for a clinical trial would have extensive preclinical data, including experience in the
preterm newborn infant and information about dosage, supporting its probable efficacy and safety.
In addition, it would be available in a stable pure form known to be free of contaminants; a suitable and
indistinguishable placebo would be available; and it would be easy to grow and identify the bacterium
in the laboratory so that colonisation of participants could be monitored and probiotic infection easily
detected. None of the interventions used in the published studies in the newborn infant fulfils these criteria.
There are also choices to be made regarding whether or not a single or multistrain product is used.
There are very few studies comparing different probiotic interventions in the preterm baby. One recent
Phase 1 study61 suggested different effects of a B. infantis species compared with B. longum in respect of
bacterial diversity and total counts of bifidobacteria, particularly when augmented by administration of
maternal milk. A second study62 comparing a product containing a single strain of B. breve with a product
providing the same quantity of B. breve together with two species of B. longum suggested that the
three-strain product was associated with increased colonisation with B. breve and fewer Enterobacteriaceae
species; whether or not these effects are attributable to the diversity or to the greater bacterial load of the
three-strain product is unclear.
Of the 12 trials included in Table 1, four used products containing a single strain, three contained different
strains of Lactobacillus, one contained B. lactis BB12 and the remaining four studies used combinations of
up to six different bacterial strains. In large part, the choice of product appears to have been governed by
availability and the ability to mix it with milk.
Although not explicitly stated in the text, in one trial conducted in Israel by Bin-Nun et al.,21 and reported at
a scientific meeting (Dr C Hammerman, Zedek Medical Center, Jerusalem, personal communication), the
intervention [ABC Dophilus® (Solgar®), which contained B. infantis, S. thermophilus and B. bifidus], was
selected because of anxiety about possible infection with Lactobacillus-containing products. The same
product was used in the recent and heretofore the largest published trial, ProPrems, carried out in
Australia.41 When asked about the choice, the author explained that it was not because of the bacterial
content but simply that it had been previously evaluated and shown to have efficacy against NEC incidence,
was available and could be imported under licence into Australia (Dr SE Jacobs, Royal Women’s Hospital,
Melbourne, VIC, personal communication). The formulation of that product has now changed so that it
contains Lactobacillus.
Two published meta-analyses34,63 attempt to group trials to study the effects of different organisms and
combinations, but they fail to reach clear conclusions and highlight the need for further study.
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Quality
Of the 12 trials detailed in Table 1, nine quote the manufacturer’s data describing the content of the
product but do not describe the storage conditions or any further testing to confirm the contents, their
purity or their stability through the course of trial recruitment. The B. lactis used by Mihatsch et al.36 was
checked monthly to ensure the viability and purity of the product together with the 24-hour stability
of the prepared suspension. The six-strain product used by Fernández-Carrocera et al.40 (four strains of
Lactobacillus, one of B. infantis and one of S. thermophilus) was checked twice against the manufacturer’s
quality control register and the ABC Dophilus used for the ProPrems trial41 was imported under licence
into Australia. Each batch was then subjected to independent confirmation of taxonomy and quality by
checking the probiotic content using polymerase chain reaction (PCR) and the purity by culture.
Experience with Bifidobacterium breve BBG-001
Use of B. breve BBG-001, the probiotic strain used for the PiPS trial, was first reported by a Japanese
group.43 Ninety-one infants of birthweight < 1500 g were randomised to receive active product or placebo.
The trial commenced with milk feeds, administered twice daily and continued for 28 days, by which time
82% of the active intervention group and 28% of the placebo group were colonised with B. breve BBG-001.
Clinical outcomes analysed whether or not the baby was successfully colonised with the probiotic organism.
Improved food tolerance, accelerated time to establish full feeds and increased weight gain that was
sustained after discontinuation of administration of probiotic were reported. No other clinical outcome was
published and none is available; probiotic use with this product became and remains routine in that
investigator’s department (Dr Kitajima, Osaka Medical Center and Research Institute for Maternal and
Child Health, Osaka, Japan, 2013, personal communication).
A single-site pilot study using the same product, B. breve BBG-001, was undertaken by the current
investigators.64 B. breve BBG-001 was used because at the time the study was designed it was the only
probiotic strain reported to confer any clinical benefit in the preterm baby.43 The primary objectives of the
pilot were to study whether or not the intervention was tolerated this early in development and to confirm
that colonisation was achieved with a once-daily dosage regimen. The design differed from previous
studies in that the study product was commenced within 48 hours of birth, whether or not milk feeds
had been started. This was to avoid excluding those babies at greatest risk of adverse outcomes and to
maximise the possibility of early colonisation with the probiotic organism, even in babies from whom the
responsible clinician might choose to withhold milk feeds because of a perceived high risk of NEC. The
products were prepared as described in the report by Kitajima et al.,43 but only a single 1-ml dose was
given, as opposed to the whole content of the sachet given in two or three 1-ml doses. We estimated the
dose given to be around 5 × 108 colony-forming units (CFUs) of B. breve BBG-001. The colonisation rates
we achieved were similar to those quoted by Kitajima et al.43 and the numbers of bifidobacteria in
the stools of those babies who were colonised were the same whether they were in the active intervention
or placebo groups: at 14 days, 12 out of 19 (63%) infants in the active intervention group were colonised
with a mean 7.3 [standard deviation (SD) 1.7] log10 CFUs per gram wet weight of stool and 4 out of 17
(24%) infants in the placebo group were colonised with a mean with 7.4 (SD 3.0) CFUs per gram wet
weight of stool. These data support the conclusion that B. breve had actively colonised the babies and the
same dose was therefore used in the main trial.
Forty infants of birthweight < 1500 g were randomised at a single site (Homerton University Hospital
Foundation Trust, London, UK) over a 6-month period in 2004 to receive B. breve BBG-001 or placebo;
both products were well tolerated by all babies. Quantitative microbiology was undertaken on stools.
Analysis of the stool passed closest to 28 days showed that 79% of the group receiving probiotic and 35%
receiving placebo were colonised with B. breve BBG-001; this high cross-contamination rate is comparable
with published experience43 and was considered likely to have occurred both in the milk kitchen and
between babies in the ward. All babies who commenced enteral feeding did so with maternal breast milk.
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Analysed by intention to treat, probiotic supplementation was associated with improved feed tolerance and
weight gain, and there were fewer babies with episodes of infection at 28 days (23% vs. 44%). The study
was too small to allow any estimate of an impact on the incidence of NEC (nine suspected or proven cases,
of whom five were randomised to receive probiotic and four placebo). When outcomes were analysed by
whether or not the infant was colonised with the administered probiotic, it was found that colonisation was
associated with a reduction in the number of babies with any episode of infection over the entire hospital
stay (from 66% to 24%; p= 0.017) and also that fewer colonised babies remained oxygen dependent at
36 weeks’ postmenstrual age (40% vs. 79%; p= 0.038). In addition, there was some evidence of increased
microbial diversity in the stools of colonised babies, although the numbers are small. In particular, at 28 days,
no stool of non-colonised babies was also colonised with anaerobic bacterial species; in contrast, 66% of
those colonised with B. breve BBG-001 were also colonised with anaerobic bacterial species. Colonisation
with Gram-negative organisms was high in both groups. When analysed by intention to treat, there was no
difference in the duration of antibiotic use in the two groups, but, when analysed by whether or not there
was successful colonisation, there was a significant reduction in the number of days on antibiotics over the
whole hospital stay in those colonised, from a mean of 39 days to 19 days (p= 0.04).
The intervention was continued for a shorter time period (28 days) in this pilot study than in the
subsequently published studies that found a reduction in NEC incidence with probiotic use, all of which
continued the intervention to either 36 weeks’ postmenstrual age or discharge from hospital. Two babies
randomised to receive probiotic in the pilot study developed proven NEC that was fatal: one at 29 days
and one at 30 days (one of these infants was not successfully colonised). When the PiPS trial was designed
it was recognised that babies at high risk of developing NEC may do so later than 4 weeks’ postnatal age,
it is now known from observational studies that more immature babies develop the disease at an older
postnatal age with the peak age at onset around 31–34 weeks’ postmenstrual age.65,66
Subsequent to the design of the PiPS trial, we are not aware of any published reports of the use of
B. breve BBG-001 in the newborn baby.
Regulatory status of probiotics
At the time of the pilot study using B. breve BBG-001 that we conducted in 2004,64 probiotics were considered
as food supplements and the trial was not conducted to International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice (ICH-GCP)
standard. A product given to prevent such serious complications of prematurity as NEC, late-onset sepsis and
death clearly fulfils the definition of a medicinal product used within the European Community: ‘Any substance
or combination of substances presented as having properties for treating or preventing disease in human
beings’ (Article 1, Directive 2001/83/EC).67 The regulator, the Medicines and Healthcare products Regulatory
Agency (MHRA), required that for this trial the probiotic intervention should be considered as a medicine and
the PiPS trial, unlike all other published trials investigating the use of probiotics in newborn babies, was
conducted to ICH-GCP standard.
Rationale for the design of the Probiotics in Preterm
infantS trial
When the PiPS trial was designed, there had been no published trials, apart from the study of Dani et al.,19
that reported effects of probiotics on NEC, late-onset sepsis and death, and no trials reporting benefits
of probiotic use. Despite this, in the context of the current understanding of the epidemiology and
pathogenesis of NEC and late-onset sepsis and the importance of identifying preventative strategies, the
probability that a probiotic intervention might be both efficacious and safe seemed high.
SCIENTIFIC BACKGROUND
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Choice of product
When our trial was designed, as far as we were aware the only study to report any benefit associated with
probiotic use in the newborn infant was the trial by Kitajima et al.43 published in 1997, studying nutritional
outcome, although the analysis was based on whether or not the baby had been successfully colonised
rather than by intention to treat. We were also aware that the product used in that trial, B. breve BBG-001,
had been in routine use in Japan for a number of years, seemingly without problems. These observations
underpinned our decision to use this product for our pilot study, in which we found it to be well tolerated
and confirmed that we could achieve good colonisation rates with a single daily dose.
We were keen to monitor colonisation of all participants, and B. breve BBG-001 had the further advantage
that the manufacturer was able to provide a selective strain-specific medium so that it could reliably be
cultured and identified.
Population
The study population was selected as being that at greatest risk of NEC. In particular, we were keen to
start the intervention as soon as practicable, not only because babies begin to acquire intestinal flora from
birth, whether or not fed, but also because as the clinical course progresses and complications arise we
believe that it is easier to find reasons not to recruit babies into trials and we thought it essential that we
recruit a trial population that was as representative as possible of all preterm admissions so that at trial
conclusion we could address the question of whether or not probiotics should be given routinely to
this population.
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Chapter 3 Methods
This was a multicentre, double-blind RCT.
Objective
The objective of the trial was to determine whether or not early administration of the probiotic B. breve
strain BBG-001 to preterm infants reduced the incidence of episodes of infection, NEC and death.
The trial protocol is available on the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)
website at www.nets.nihr.ac.uk.
Participants
Participants were preterm babies born between 23+0 and 30+6 weeks’ gestation and recruited with
informed signed parental consent within 48 hours of birth. Babies were eligible for recruitment whether or
not they had been born in the recruiting centre. Those with a lethal congenital malformation or any
malformation of the gastrointestinal tract detected before 48 hours or who were considered to have no
realistic chance of survival were excluded. Receiving antibiotics for proven or suspected infection was not
an exclusion criterion.
Trial sites
The trial was conducted at 57 sites. Of these, 24 were recruitment sites and 33 were sites to which
participants were transferred for continuing care. A complete list of the recruitment sites is available in
Appendix 1.
Interventions
The active intervention was B. breve BBG-001, suspended in one-eighth strength of the infant formula
Neocate® (Nutricia Ltd, Trowbridge, UK). The placebo was one-eighth-strength Neocate. A description
of Neocate is available at www.neocate.co.uk/uploadedFiles/Neocate/Resources_Library/Documents/
Neocate_LCP_data_card.pdf (accessed 26 August 2016).
The probiotic and placebo powders were manufactured and supplied by the Yakult Honsha Co. Ltd
(Tokyo, Japan) in identical square foil sachets each containing 1 g of product. The sachets of active product
contained B. breve BBG-001 freeze-dried with maize starch and those of placebo contained freeze-dried
maize starch alone; the appearance of the powders was identical. The trial was conducted using a single
batch of products manufactured specifically for this study, the release criteria for this batch stated that
each sachet of the active product contained between 2 × 108 and 2 × 1010 CFUs. After importation to the
UK, the sachets were packed at Bilcare Global Clinical Supplies (Europe) Ltd into packages each containing
91 sachets (the maximum number of sachets a baby might require) of either active product or placebo.
Each of the 91 sachets and the package was labelled with a unique five-digit alphanumeric identifier.
Product preparation, administration and blinding
The manufacturer’s instructions involved suspending the powders in water, allowing the maize starch to
settle for 30 minutes and administering the supernatant within the next 2.5 hours. Prepared in this way,
the supernatant of the active product was cloudy and that of the placebo clear. This was overcome by
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substituting one-eighth-strength Neocate for the water. Occasionally the turbidity of the supernatant still
varied slightly and, therefore, to be completely confident that the active intervention and placebo were
indistinguishable, they were prepared in specially manufactured amber-coloured bijou bottles (Figure 1).
Kitajima et al.,43 using the same product, prepared it using 2ml of water. During our preliminary work we
found that when using 2ml that it was sometimes difficult, using a syringe, to withdraw 1ml without
disturbing the maize starch residue. We were keen not to increase the volume that we were administering
to the babies but equally keen to ensure, with minimal evidence to guide us, that we gave adequate
numbers of bacteria. By a process of trial and error we found that, if we increased the volume used to
suspend the powder to 3ml, then only rarely were we unable easily to withdraw 1ml. We emphasised to
investigators the importance of not disturbing the maize starch and suggested that, if they had any
difficulty withdrawing 1ml, they could simply give less on that day.
The products were prepared in the milk kitchens on the neonatal units of the participating hospitals,
usually by one of the nurses engaged in clinical care. In order to minimise the possibility of cross-contamination
of the placebo by B. breve BBG-001, members of the trial team provided on-site training with an emphasis
on handwashing and decontamination of working surfaces in between preparing each baby’s intervention.
This teaching was repeated, on request, for new staff and was supported with detailed guidance on
laminated sheets for display in milk kitchens. The guidance sheet for product preparation is available
in Appendix 2.
Dosage
The range of values quoted by the manufacturers of products used in published trials is from 106 to 109
CFUs per dose. The dose used in the study of Kitajima et al.43 is the most relevant for this trial because the
same product was used. The babies in the study of Kitajima et al.43 were given the contents of a whole
sachet (estimated in the publication to contain 1 × 109 CFUs) in two or three divided doses (i.e. 3.3 × 108 to
5.0 × 108 CFUs per dose) each 1ml in volume. In our pilot study we achieved colonisation rates similar to
Kitajima et al.43 with a single dose. The manufacturer stated that each sachet of the batch used for the
PiPS trial contained between 2 × 108 and 2 × 1010 CFUs. Preparing the product as we did, using 3ml of
Neocate, suggests that the range of bacterial counts in a 1-ml dose would be between 6.7 × 107 and
6.7 × 109 CFUs of B. breve BBG-001.
A record was kept of doses omitted and of sachets wasted, and was reconciled centrally against the
number of unused sachets in the package after it was collected by the trial research nurses when the baby
had completed the intervention.
Administration
The intervention was prescribed using the five-digit alphanumeric identifier for the pack allocated for that
baby. This was written on the side of the bijou bottle during preparation and checked by the nurses before
administration. A feeding syringe was used to withdraw 1ml of supernatant, which was given to the baby.
FIGURE 1 Prepared product in amber-coloured bijou bottle.
METHODS
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Extension of the shelf-life of the interventions: viability counts for B. breve
BBG-001 in the active intervention
The manufacturer supplied data documenting the decline of viability and lack of contamination of previous
batches of the product extending for 42 months from manufacture. As there was a lack of evidence
beyond that time, the stated shelf life for the batches provided for the PiPS trial extended to the end of
August 2012 for the active product and September 2012 for the placebo. During 2011 and 2012 it
became clear that recruitment would need to continue until mid-2013 and that a second batch of
interventions would be needed. It emerged that circumstances had changed and that new batches of
intervention, particularly of placebo, could not easily be provided. We knew from work with the previous
batch of the active product used for the pilot study and from monitoring undertaken in the early stages of
this trial that the counts of viable B. breve BBG-001 were declining only slowly.
In the absence of any other guidance we accepted 2 × 108 (8.3 log10) CFUs of B. breve BBG-001 per sachet
(6.7 × 107 or 7.8 log10-CFUs per dose) as the minimum figure that we should accept for this trial.
Analysis of unused sachets returned from centres during the early stages of the PiPS trial had been carried
out and corrected to give the viable count per 1-ml dose. A plot of these data (Figure 2) showed a gradual
decline in viable counts (solid blue line). The manufacturer provided stability data from two different
batches of material for 42 months from manufacture, shown as CFUs per sachet for comparison (see
Figure 2, solid black and green lines). All three lines are roughly parallel and extrapolation from the data
obtained from the batch being used for the PiPS trial indicated that the number of viable organisms per
dose would remain well above 6.7 × 107 or 7.8 log10-CFUs for at least 48 months (i.e. until October 2013)
and probably beyond.
On the basis of these data, a successful application was made to the MHRA to extend the shelf life of both
probiotic and placebo to the end of October 2013 and all sachets and boxes were relabelled accordingly.
It was agreed that we should continue to monitor the counts of viable bacteria in a randomly selected
unused sachet from each pack after the baby had completed its course of treatment to confirm both that
the rate of decline was not accelerating and that the products remained free of contamination. It was
agreed that if the viable counts fell below 2 × 108 CFUs (8.3 log10-CFUs) per sachet, or if any contamination
was identified, recruitment would stop.
Outcomes
The rationale and definitions of outcomes are detailed in appendices 1–4 of the trial protocol, which is
available on the NETSCC website.68
Primary outcomes
l Any baby experiencing an episode of bloodstream infection, with any organism other than a skin
commensal, diagnosed on a sample of blood drawn more than 72 hours after birth and before
46 weeks’ postmenstrual age, death or discharge from hospital, whichever is soonest. Skin commensals
include coagulase-negative staphylococci and Corynebacterium.
l NEC, Bell stage 2 or 3.
l Death before discharge from hospital.
Secondary outcomes
1. Number of babies with the composite outcome of any or a combination of the three primary outcomes.
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Secondary microbiological outcomes
Outcomes 2–7 are for samples taken > 72 hours after birth and before 46 weeks’ postmenstrual age,
death or discharge home:
2. Number of babies with any positive blood culture with an organism recognised as a skin commensal
(e.g. coagulase-negative staphylococci or Corynebacterium).
3. Number of babies with blood cultures taken.
4. Number of blood cultures taken per baby.
5. Number of babies with episodes of bloodstream infection with organisms other than skin commensals
by organism, for example Escherichia coli, Klebsiella spp., fungi, and by antibiotic resistance types,
specifically meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE)
and extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria.
6. Number of babies with isolates of organisms other than skin commensals from a normally sterile site
other than blood, for example cerebrospinal fluid, suprapubic aspiration of urine, pleural cavity, etc.
7. Number of babies with a positive culture of B. breve BBG-001 from any normally sterile site.
In addition:
8. Total duration of days of antibiotics and/or antifungals administered per baby after 72 hours and until
46 weeks’ postmenstrual age, death or discharge from hospital, whichever is soonest, for treatment of
suspected or proven late-onset sepsis, that is, excluding prophylactic use.
9. The number of babies colonised with the administered probiotic strain defined by the isolation of
B. breve BBG-001 from stool samples at 2 weeks’ postnatal age and at 36 weeks’ postmenstrual age.
10. Stool flora: the number of babies colonised with MRSA, VRE or ESBL at 2 weeks’ postnatal and
at 36 weeks’ postmenstrual age.
Nutritional and gastroenterological outcomes
11. Age at achieving full enteral nutrition (defined as 150ml/kg/day for 1 day).
12. Change of weight z-score from birth to 36 weeks’ postmenstrual age or discharge from hospital
if sooner.
Other clinical outcomes
14. Bronchopulmonary dysplasia.
15. Hydrocephalus and/or intraparenchymal cysts confirmed by cerebral ultrasound scan performed during
the baby’s inpatient stay.
16. Worst stage of retinopathy of prematurity in either eye at discharge or death.
17. Length of stay in intensive, high-dependency and special care unit.
Randomisation
Randomisation was performed by health-care staff trained in trial procedures and named on the trial
delegation log.
Randomisation to receive either probiotic or placebo used a central web-based service, with telephone
back-up, based at the National Perinatal Epidemiological Unit (NPEU), University of Oxford, Oxford, UK.
The randomisation program used a minimisation algorithm to ensure balance across site, sex, gestational
age at birth (23, 24, 25, 26/27 and 28–30 weeks’ gestation) and whether or not randomisation occurred
sooner than 24 hours after birth.
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At randomisation the investigator was given a unique five-digit study number for the baby, which was the
principal identifier throughout the trial, and a five-digit alphanumeric number for the intervention pack to
be used.
Parents, clinicians and outcome assessors were blind to the allocation.
Trial procedures
Consent
Whenever possible, preliminary discussions supported by written information about the trial would be
offered to parents before the birth if the baby was likely to be eligible. This happened both at recruiting
centres and at local hospitals that routinely referred babies into the recruiting centres. Informed written
consent was sought from a parent after the birth only when they had been given a full oral and written
explanation of the study. Copies of the parent information leaflet, the consent form and the leaflet
provided to investigators summarising the material that should be covered in discussions about the trial are
available in Appendices 3–5.
Investigators were encouraged to discuss the trial with parents periodically during the hospitalisation to
confirm their continued understanding and willingness to participate.
At all stages it was made clear to the parents that they remained free to withdraw their baby from the
study at any time with no need to provide an explanation. When babies were transferred between
hospitals, the parents were given written information including the name of the consultant acting as
principal investigator (PI) at the receiving hospital.
Parents who did not speak English were approached only if an appropriate adult interpreter was available.
Withdrawal from the trial
When parents requested that their baby be withdrawn from the trial, we completed an additional data
form (see form 6, Appendix 6) that clarified whether or not it was only administration of the intervention
that was to be discontinued and whether or not the parents were willing for data already collected,
for outstanding data and/or stool collection to continue and for those data to be used.
Clinical care of participants
The day-to-day clinical care of participants was entirely at the discretion of the responsible clinical team.
Investigators were encouraged to use maternal breast milk, but feeding regimes were not standardised.
Discontinuation of the trial intervention
Whether or not the intervention was discontinued temporarily when babies were unwell was at the
discretion of the parents and attending clinical staff. The only circumstance in which clear advice was given
to withhold a dose was when intestinal perforation was suspected.
Stool sample collection
Stool samples were collected as close as possible to 14 days’ postnatal and 36 weeks’ postmenstrual age.
These times were chosen for practical reasons, the main objective being to gain a snapshot of stool colonisation
by B. breve BBG-001 as a marker of intestinal colonisation. It was considered that, at 2 weeks of age, enteral
feeds would be established in the majority of babies, who would have received the intervention for over a
week, while still being before the time, for this population, of the peak incidence of NEC. Thirty-six weeks was
selected, as this is the time at which outcome data describing bronchopulmonary dysplasia and growth were
reported. Investigators were asked, if possible, to send three full scoops of stool. Samples were posted for
processing to the Microbiology Laboratory at the Royal London Hospital, Barts Health NHS Trust, UK, using the
Thermacor transportation system for diagnostic samples (Dyecor Ltd, Hereford, UK) and the Royal Mail.
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
No other biological samples were collected.
Data collection
With the exception of detailed results of routine microbiological investigations, all trial data were collected
onto paper forms, which were posted to the NPEU Clinical Trials Unit for checking and double-entered
onto a web-based clinical database, OpenClinica (OpenClinica, LLC, Waltham, MA, USA). Data were
entered in accordance with NPEU Clinical Trials Unit OpenClinica data entry conventions. All personal
details were entered into a Microsoft Access® 2013 database (version 15, Microsoft Corporation,
Redmond, WA, USA).
Form 1: trial entry (see Appendix 7)
Part A of this form had to be completed and the answers available to facilitate randomisation and parts
B–F of the form comprised baseline maternal and neonatal information. It was requested that it was
posted to the trial office within 1 week of birth.
Form 2: daily data collection (see Appendix 8)
The aim of this form was to collect details of enteral feeds and antimicrobial interventions for the first
14 days of life until the collection of the first stool sample so as to enable later detailed analysis of
determinants of colonisation at 14 days with B. breve BBG-001. If the baby was transferred between
hospitals during this time, then a copy was retained at the referring hospital and the original form
accompanied the baby.
Form 3: clinical details of baby at transfer, discharge or death
(see Appendix 9)
This form provided clinical details and was due for completion at discharge from hospital, at death or
if the baby was transferred to a different hospital, that is one form was completed for each admission
and a baby could accrue multiple forms. If the baby reached 36 weeks’ postmenstrual age during the
admission, the details of growth and respiratory support to determine whether or not the baby had
bronchopulmonary dysplasia were provided. The form included a question about whether or not the baby
had experienced any episode of NEC or other abdominal pathology which, if affirmative, led to completion
of form 4.
Form 4: abdominal pathology (see Appendix 10)
This form was completed for any episode of suspected abdominal pathology. Multiple forms, each for a
different episode, might be completed during a single admission covered by a single form 3 and if a baby
was transferred between hospitals for specialist management of NEC multiple forms might be received
from different hospitals for the same episode. The staging of an episode of NEC was primarily based on
that provided by the clinician on the form but the form included questions about the clinical characteristics
of the episode with the intention that these would later be checked to confirm consistency with the stated
NEC staging.
Form 4 review
All cases in which any form 4 had been received were reviewed by Professor Kate Costeloe (chief
investigator), Dr Kenny McCormick (consultant neonatologist, PI for the PiPS trial at the John Radcliffe
Hospital, Oxford, UK) and Mrs Michele Upton (PiPS research nurse), to determine the number of discrete
episodes of NEC, the highest Bell staging of any NEC episode, the age at onset of the first episode of any
NEC and of stage 2 or 3 NEC and the agreed diagnosis of episodes of other abdominal pathologies.
The review involved scrutiny of all forms 4 together with the associated forms 3 and, when relevant, with
postmortem reports and operation notes. Outstanding inconsistencies and queries were resolved together
with the PIs with reference to the contemporaneous medical records.
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Routine microbiological data
The results of routine microbiological investigations together with the antibiotic sensitivities of cultured
bacteria were obtained directly from the staff in the laboratories of participating hospitals on an Microsoft
Excel® 2010 spreadsheet (Version 14, Microsoft Corporation, Redmond, WA, USA). They were scrutinised
individually by Dr Michael R Millar to ensure that all positive cultures from normally sterile sites were
identified. All positive cultures were entered onto the trial database together with the sampling site,
species of bacteria and patterns of antibiotic resistance. The accuracy of the trial microbiological data was
checked by comparing 20% of trial data entries against the Microsoft Excel-recorded laboratory returns.
Safety and adverse event reporting
Unexpected serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs)
were reported using form 5 (see Appendix 11). Two SUSARs were noted prospectively:
1. intestinal obstruction associated with maize starch
2. bacteraemia with B. breve BBG-001.
Stool samples: microbiology methods
All samples were processed in the microbiology laboratory at Barts Health NHS Trust. When multiple
samples were received from the same infant, then the sample collected closest to the appropriate date
(14 days postnatal age or 36 weeks’ postmenstrual age) was selected for storage and analysis.
The microbiology laboratory at Barts Health NHS Trust is accredited through Clinical Pathology
Accreditation (UK) Ltd (a wholly owned subsidiary of the United Kingdom Accreditation Service).
The procedures used in this study, such as those used for culture, identification, antibiotic sensitivity
testing of organisms and disposal of waste, were performed in accordance with laboratory standard
operating procedures.
On receipt into the laboratory, specimens were weighed and divided in to two equal parts. The study
number and date of receipt of each specimen were recorded. Half was frozen and stored at –80 °C;
this sample was collected to allow additional chemical, immunological and molecular analyses including
the molecular detection of the trial strain (B. breve BBG-001). The other half was diluted 1 : 10 in a
cryopreservative broth [brain–heart infusion broth (Oxoid Microbiological Products Ltd, Basingstoke, UK)
containing 10% glycerol (weight/volume)], mixed by vortexing for 10 seconds, and then placed in 1-ml
aliquots into sterile 1.5-ml Eppendorf tubes (Eppendorf AG, Hamburg, Germany) before freezing at –80 °C.
Detection of Bifidobacterium breve BBG-001, meticillin-resistant
Staphylococcus aureus, vancomycin-resistant enterococci and
extended-spectrum beta-lactamase-producing Gram-negative bacteria in
stool samples by culture
Samples were batch processed. Vials of frozen sample in cryopreservative were allowed to thaw at room
temperature, and 100 µl of the faecal broth was serially diluted in phosphate-buffered saline. Aliquots of
100 µl of the neat, 10−1, 10−3 and 10−5 dilutions were inoculated onto the agar medium plates.
Selective media were used for the detection of the trial strain (B. breve BBG-001), MRSA, VRE and
ESBL-producing Enterobacteriaceae. The selective medium used for detection of the B. breve BBG-001 was
Trypticase® peptone oligosaccharide (TOS) agar (Yakult Honsha Ltd, Japan) containing carbenicillin
(10 µg/ml) and streptomycin (50 µg/ml). TOS agar was incubated for 48–72 hours anaerobically.
ESBL-producing Enterobacteriaceae were cultured using MacConkey agar (Oxoid Microbiological Products
Ltd, Basingstoke, UK) and Brilliance™ ESBL agar (Oxoid Microbiological Products Ltd), MRSA using
mannitol salt agar with oxacillin (Oxoid Microbiological Products Ltd) and VRE using Slanetz and Bartley
agar with vancomycin (Oxoid Microbiological Products Ltd). Inoculated selective media for MRSA, VRE and
ESBL were incubated at 37 °C for 24–36 hours in air.
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Identification and enumeration of cultured Bifidobacterium breve
Bifidobacterium breve produces a characteristic white convex colony on TOS agar. The faecal concentration
of B. breve was determined by counting the number of colonies of faecal dilutions on TOS agar,
allowing estimation of the numbers in the undiluted samples. Cultured colonies were identified using
matrix-assisted laser desorption/ionisation time of flight (MALDI-TOF) mass spectrometry (Bruker UK Ltd,
Coventry, UK). In the early phase of the study the identification of a proportion of representative colonies
was confirmed by 16S ribosomal deoxyribonucleic acid (DNA) sequencing.
Identification and enumeration of antibiotic-resistant bacteria
Bacterial colonies growing on selective agars were enumerated. Isolates were identified using standard
laboratory methods including MALDI-TOF mass spectrometry (Bruker UK Ltd, Coventry, UK). MRSA
and VRE isolates were identified as MRSA or VRE using British Society for Antimicrobial Chemotherapy
methods and interpretive criteria.69 Gram-negative bacilli which grew on MacConkey or Brilliance ESBL
agar were tested for susceptibility to a range of antibiotics using British Society for Antimicrobial
Chemotherapy methods.69 Antibiotics tested included cefuroxime, ceftazidime, cefpodoxime, ampicillin,
gentamicin, piperacillin/tazobactam, amoxicillin with clavulanate, tetracycline, trimethoprim, amikacin,
tobramycin, imipenem, ertapenem, tigecycline, colistin, ciprofloxacin, aztreonam and chloramphenicol.
Antibiotic-resistant isolates were stored by emulsification of colonies into microbank storage vials (Pro-lab
Diagnostics, Wirral, UK) and stored at –80 °C.
Molecular detection of Bifidobacterium breve strain BBG-001 in
stool samples
Deoxyribonucleic acid was extracted from faecal matter using the QIAamp DNA stool minikit (Qiagen Ltd,
Manchester, UK) in accordance with the manufacturer’s instructions with an added bead-beating step. A
strain-specific quantitative real-time PCR method previously reported by Fujimoto et al. in 201170 was used
to detect B. breve BBG-001. The forward PCR primer sequence was 5′-ATGGCAAAACCGGGCTGAA-3′ and
the reverse 5′-CCCACCTCTCATCCGC-3′ to give a 313-bp PCR product. Amplification and detection was
carried out in 96-well optical low-profile plates (Anachem Ltd, Luton, UK) on a Bio-Rad CFX 96 real-time
PCR machine-C1000 thermal cycler (Bio-Rad, Hercules, CA, USA). The PCR assay was re-optimised for use
on the Bio-Rad machine with a fast PCR mix. Several PCR mixes were tested (Bio-Rad, Molzym and Agilent).
The annealing temperature was optimised using the temperature gradient function of the Bio-Rad PCR
machine. A primer titration was also performed.
Each PCR reaction (final/total volume of 10 µl) contained 1 µl of DNA template, 400 nM of each PCR
primer, and 2 × Brilliant III Ultra-Fast QPCR Master Mix (Agilent Technologies, Santa Clara, CA, USA). The
313-bp target sequence was amplified with an initial hold of 3 minutes at 95 °C followed by 40 cycles of
5 seconds at 95 °C and 10 seconds at the optimised annealing temperature of 62 °C. The melt cycle
involved a temperature ramp from 65 °C to 95 °C, with a 5-second hold at each 0.5 °C step of the ramp.
Each sample was analysed in triplicate at neat and 1 : 10 concentration to check for PCR inhibition.
A no-template control, a faecal extraction-negative control and a faecal extraction-positive control were
also included on each PCR run. A sample was scored as positive if there is amplification for two or
three out of three replicates with a melt curve at 87 °C, 82 °C or 85 °C, because we found that the
strain-specific sequence derived from stool samples did sometimes give an 82 °C or 85 °C melt curve.
Purified B. breve BBG-001 DNA produced a melt curve of 87 °C. Serial 10-fold dilution standards were run
on each plate using the trial strain DNA at concentrations from 30 ng/µl to 30 fg/µl to allow estimation of
the quantity of B. breve BBG-001 in each sample.
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Data validation
Validation programs performed a series of range, logic and missing data checks to identify any
inconsistencies within and across forms on an ongoing basis. Some queries were resolved at the NPEU
according to predefined protocols; those that could not be resolved were reconciled between the staff in
the trial office, the PiPS trial research nurses, chief investigator and PI with reference to the clinical record,
and documented accordingly.
Sample size
Estimating sample size was difficult because of the paucity of reliable contemporary outcome data by
gestational age. Based on data collected for local service appraisals around the year 2000, it was thought
that the event rate of each of the primary outcomes might be as high as 15%. At a two-sided significance
level of 5%, a trial of 1300 infants would have 90% power to detect a 40% relative risk (RR) reduction
from 15% to 9.1%, or a 44% RR reduction from 12% to 6.7% or from 10% to 5.6% for each of the
primary outcomes. These reductions were deemed to be of clinical importance by the investigators.
Recruitment targets
The aim was to begin recruitment within 6 months of trial commencement in September 2009, to recruit
300 babies in the first 3 months and accelerating gradually so that thereafter an average of 50 babies
were recruited each month, with a total recruitment time of 2 years and 6 months.
Statistical methods
The full statistical analysis plan is available in Appendix 12.
The comparison of primary interest was whether or not there was a difference between the groups of the
trial in any of the three primary outcomes. The primary analysis of primary and secondary outcomes was by
intention to treat, that is the outcomes were compared across randomised groups for all infants recruited
regardless of whether or not, or for how long, they received the allocated PiPS trial interventions.
Adjusted analyses were performed on all comparative analyses adjusting for the variables used in the
minimisation algorithm, hospital, sex, gestational age at birth (23, 24, 25, 26/27 and 28–30 weeks’
gestation), and whether or not randomisation occured sooner than 24 hours after birth. The adjusted
analyses also took into account correlation of outcomes between participating babies from multiple births.
For binary outcomes, for example whether or not a baby ever had an episode of infection, adjusted RRs
and CIs were calculated. For continuous outcomes, for example the number of episodes of infection,
adjusted differences in means or unadjusted differences in medians (depending on the distribution of the
data) were calculated with CIs. Analysis of time-to-event outcomes, such as reaching full enteral feeding,
used survival analysis techniques.
Subgroup analyses included an interaction test and, when appropriate, results are presented as adjusted
RRs with 95% CIs.
Prespecified subgroup analyses were performed on the primary outcomes by intention to treat,
stratified by:
l whether or not randomised in the first or second 24 hours after birth
l gestational age at birth as per minimisation: 23, 24, 25, 26/27 and 28–30 weeks’ gestation
l male versus female
l colonised versus not colonised at 2 weeks’ postnatal age
l gestational age < 28+0 or ≥ 28+0 weeks’ gestation.
METHODS
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An additional subgroup analysis was performed post hoc by birthweight above or below 1 kg to facilitate
comparison with data from the published ProPrems trial41 and to address recommendations made
in successive systematic reviews30,32,35 concerning routine administration of probiotics in these
birthweight categories.
A secondary analysis of all clinical and microbiological outcomes was conducted in those babies for whom
stool colonisation data were available at 2 weeks’ postnatal age by whether or not the baby was colonised
with B. breve BBG-001 identified by either culture or PCR.
Determinants of successful colonisation at 2 weeks’ postnatal age in those babies analysed to receive
probiotics were investigated using forward stepwise regression. The factors assessed were baseline
characteristics together with day of first feed, type of milk, use of antacid and administration of antibiotics
beyond the fifth day after birth.
Significance levels and multiplicity
The 95% CIs are presented for all analyses on the primary outcomes, and a significance level of 5%
(consistent with a 95% CI) used to indicate statistical significance.
Owing to the large number of secondary outcomes, all analyses are presented with 99% CIs and a
significance level of 1% (consistent with a 99% CI) is used to indicate statistical significance.
The p-values are not presented for comparative analyses, but are for tests of interaction.
Regulatory approvals and protocol changes
Version 1.0 of the protocol, dated 29 January 2009, was approved by the South Central Oxford A Ethics
Committee on 12 May 2009. The name of the trial was changed from PREFER to PiPS (as a condition of
approval from the ethics committee) and this resulted in the protocol being amended to version 2.0, dated
18 May 2009.
Two changes to the conduct of the trial resulted in protocol version 3.0 (dated 6 October 2009): the way
the investigational medicinal product (IMP) was allocated (from study number to pack number) and the
duration of daily data collection of milk feeds and antibiotic/antifungal usage (from ‘until full feeds
reached’ to ‘until 2 weeks’ postnatal age’). Minor typographical changes resulted in version 3.1 (dated
3 February 2010), and an update to include a more recent appraisal of the literature on Bifidobacterium
use in infants led to version 4.0 (dated 13 April 2010).
Two sections relating to safety reporting and the addition of continuing care sites were updated in March
2010 (version 5.0, dated 17 March 2011). Clarification was made to safety reporting at different ‘levels’
of sites to state that safety will be assessed continuously and reported irrespective of site status. The
description of how the addition and set-up of continuing care sites was achieved in practice was updated,
and the implementation of the generic site-specific application system and ‘statement of responsibilities’
for gaining approvals of continuing care sites that fell outside recognised clinical pathways for transfers
was added. All of these amendments received Research Ethics Committee approval.
A number of changes to the trial protocol resulted in version 6.0 (dated 24 July 2012). The background
and rationale section of the protocol was updated with information from the latest publications, and the
window for primary outcome data for late-onset sepsis and secondary outcome data collection for
microbiological culture and antibiotic/antifungal use was ‘closed’ at 46 weeks’ postmenstrual age for those
babies still in hospital. A paragraph was added to appendix 6 of the protocol about the identification of
carbapenem (imipenem, meropenem)-resistant Enterobacteriaceae cultures from stool samples taken
from the PiPS trial participants and the procedure for alerting sites of this finding. Details of flagging in
sections 3.11 and 10.6 of the protocol were modified to reflect changes in the current Medical Research
Information Service system and what services could be provided under the current project remit. The lower
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limit of eligibility for gestational age, which had not been clear in previous versions of the protocol, was
explicitly defined. The specified dose range for the IMP was changed from between 2.2 × 109 and 3.2 × 109
CFUs to between 6.7 × 107 and 6.7 × 109 CFUs along with the expiry date for the IMP and placebo in
substantial amendment number 5. References to this specification range in the protocol were all updated
to reflect this change.
The final version of the protocol (version 6), dated July 2012, is available on the NETSCC website at
www.nets.nihr.ac.uk. All other trial documents are listed in Table 2, with details of amendments and
version change.
TABLE 2 Versions of trial documents other than the protocol that were in use at the end of the trial with details
of amendments
Study document
Version as of
April 2014 Changes
Consent form Version 3.1,
20 January 2010
Amendments made before the start of recruitment included
additional questions for flagging of babies and use of personal
identifiable data. Minor amendments to wording of question on
confidentiality (to be in line with National Information Governance
Board for Health and Social Care recommendations), form design
and instructions on how to use it
Parent information leaflet Version 5.1,
14 February 2011
Amendments made during recruitment included minor formatting
and typographical errors changes, updating of text on participant
‘flagging’ and consent for providing primary care trust details (in
line with NHS Information Centre recommendations), and an
update to the current appraisal of literature on probiotic use in
infants
General practitioner letter Version 3.0,
25 July 2012
Amended at the time of sending to change the trial name from
PREFER to PiPS and to add the mother’s name and date of birth
Transfer contact sheet Version 1.0,
21 March 2010
No amendments. For parents of babies that have been transferred
between hospitals. This document will give the contact details of
the study team at the receiving hospital
Form 1: trial entry Version 3.0,
20 June 2011
Amendment during recruitment. Correction of clerical errors, minor
formatting of form design, and addition and clarification of
instructions
Form 2: daily data collection Version 3.0,
21 March 2011
Addition during recruitment of a question about stool collection
and instructions for form completion. Correction of clerical errors
and clarifications
Form 3: clinical details of baby
at transfer, discharge or death
Version 4.0,
20 June 2011
Addition during recruitment of questions clarifying stool collection
and the date of last dose, removal of redundant questions on
respiratory support. Correction of clerical errors, minor formatting
to form design and addition of instructions
Form 4: abdominal pathology Version 3.0,
20 June 2011
Removal during recruitment of a redundant subquestion on NEC,
correction of clerical errors, minor formatting to form design and
addition of instructions
Form 5: SAE/SUSAR reporting Version 2.0,
30 June 2010
Correction prior to the beginning of recruitment of clerical errors,
minor formatting to form design and addition of instructions
Form 6: discontinuation or
withdrawal
Version 3.0,
20 June 2011
Correction during recruitment of clerical errors, minor formatting
to form design and addition of instructions
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Monitoring
Central monitoring was performed throughout the trial by the NPEU Clinical Trials Unit co-ordinating
centre to ensure that case report forms were complete and to detect unusual patterns and outliers in data.
In addition, on-site monitoring was completed for 98% of participating sites, which involved inspection of
site files and checks on compliance with trial procedures and good clinical practice (GCP). Site audits and
source verification of data were carried out only if ‘triggered’ by central monitoring or from routine site
visits undertaken by PiPS research; no such triggers occurred during the trial.
Trial oversight and patient and public involvement
The trial was overseen by an independent Trial Steering Committee and Data Monitoring Committee. The
Trial Steering Committee first met during the planning stages of the trial and supported the investigators
while clarification was being obtained from the MHRA around the status of probiotics and the requirement
for a Clinical Trial Certificate. Thereafter, the committees met annually.
The membership of the Trial Steering Committee included a representative of the preterm baby charity
Bliss who represented parents and who advised mainly on the development of the trial and the production
of parent information.
The general conduct of the trial was managed by a trial co-investigators group including investigators,
trial co-ordinator, research nurses, statisticians and other staff of the NPEU who met every 4–6 weeks.
Results
A total of 1315 infants were recruited from 24 hospitals within 60 miles of London (UK) over 37 months
from July 2010. Details of recruitment, by site, are given in Table 3. The start of recruitment was delayed
by 3 months so that it began 9 months after the core trial staff came into post; recruitment rates were
initially slow, so that after 9 months only 121 babies had been recruited and it was 17 months before
50 babies were recruited in 1 month (Figure 3).
It subsequently emerged that a total of six protocol deviations concerning baseline data items had occurred
at randomisation: one infant in each group was over 48 hours old and two in each group were outside
the target gestational age range (Table 4).
There was almost complete retrieval of data entry forms (Table 5).
The parents of five babies withdrew consent for all participation, including for the use of data already
collected (Figure 4).
Of the 1315 babies randomised, eight never received any intervention (seven of these died within 1 week
of birth and one was transferred early to a hospital without the necessary regulatory approvals to
administer the intervention). Two babies randomised to receive placebo were wrongly allocated
probiotic packs.
Interim analyses
Interim analyses were undertaken when entry data for 371 babies and outcome data for death and NEC
were available for 138 babies and again when entry data for 936 babies and outcome data for 598 babies
were available. The results were reviewed by the Data Monitoring Committee, which recommended that
recruitment should continue with no changes in target numbers.
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TABLE 3 Recruitment by site
Hospital Start date
Total
recruited
Consent
withdrawn
for use of
data, n
Allocated
to receive
probiotic,
n (%)
Allocated
to receive
placebo,
n (%)
Homerton University Hospital, London 10 June 2010 263 3 126 (19.4) 134 (20.3)
Royal London Hospital, London 21 July 2010 74 – 37 (5.7) 37 (5.6)
Whipps Cross University Hospital,
London
4 August 2010 28 – 14 (2.2) 14 (2.1)
Queen’s Hospital, Romford, London 20 August 2010 60 – 29 (4.5) 31 (4.7)
Newham University Hospital, London 24 September 2010 66 – 32 (4.9) 34 (5.2)
Medway Maritime Hospital, Kent 21 October 2010 76 – 40 (6.2) 36 (5.5)
St Thomas’ Hospital, London 29 October 2010 97 2 46 (7.1) 49 (7.4)
North Middlesex University Hospital,
London
3 December 2010 22 – 11 (1.7) 11 (1.7)
St Peter’s Hospital, Chertsey 8 December 2010 96 – 46 (7.1) 50 (7.6)
William Harvey Hospital, Ashford, Kent 9 December 2010 61 – 29 (4.5) 32 (4.9)
Whittington Hospital 24 January 2011 9 – 6 (0.9) 3 (0.5)
King’s College Hospital, London 11 February 2011 23 – 12 (1.9) 11 (1.7)
Southend University Hospital, Essex 11 February 2011 21 – 11 (1.7) 10 (1.5)
Barnet Hospital, London 16 February 2011 31 – 15 (2.3) 16 (2.4)
University College Hospital, London 16 February 2011 93 – 45 (6.9) 48 (7.3)
University Hospital, Lewisham, London 22 February 2011 24 – 12 (1.9) 12 (1.8)
St George’s Hospital, London 4 April 2011 56 – 28 (4.3) 28 (4.2)
Croydon University Hospital, London 28 April 2011 11 – 7 (1.1) 4 (0.6)
John Radcliffe Hospital, Oxford 12 May 2011 71 – 36 (5.5) 35 (5.3)
Luton and Dunstable University
Hospital, Herts
20 June 2011 32 – 16 (2.5) 16 (2.4)
Watford General Hospital 20 June 2011 27 – 14 (2.2) 13 (2.0)
Tunbridge Wells Hospital at Pembury,
Kent
1 October 2011 35 – 19 (2.9) 16 (2.4)
Basildon University Hospital, London 10 November 2011 11 – 5 (0.8) 6 (0.9)
Royal Sussex County Hospital, Brighton 4 May 2012 28 – 14 (2.2) 14 (2.1)
Total 1315 5 650 660
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
10
0 0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
10
00
11
00
12
00
13
00
A
ct
u
al
Pr
ed
ic
te
d
Ju
ly 
20
10
Total number of recruits by month
M
o
n
th
Se
pt
em
be
r 2
01
0
No
ve
m
be
r 2
01
0
Ja
nu
ar
y 2
01
1
M
ar
ch
 20
11 M
ay
 20
11
Se
pt
em
be
r 2
01
1
No
ve
m
be
r 2
01
1
Ja
nu
ar
y 2
01
2
M
ar
ch
 20
12 M
ay
 20
12
Ju
ly 
20
11
Ju
ly 
20
12
Se
pt
em
be
r 2
01
2
No
ve
m
be
r 2
01
2
Ja
nu
ar
y 2
01
3
M
ar
ch
 20
13 M
ay
 20
13 J
ul
y 2
01
3
FI
G
U
R
E
3
R
at
es
o
f
re
cr
u
it
m
en
t
fr
o
m
Ju
ly
20
10
.T
h
e
ta
rg
et
o
f
12
94
re
cr
u
it
s
st
at
ed
in
th
e
p
ro
to
co
lw
as
re
ac
h
ed
af
te
r
36
m
o
n
th
s
b
u
t
th
e
p
ro
je
ct
m
an
ag
em
en
t
g
ro
u
p
,
h
av
in
g
fi
rs
t
co
n
fi
rm
ed
w
it
h
th
e
R
es
ea
rc
h
Et
h
ic
s
C
o
m
m
it
te
e,
ex
te
n
d
ed
re
cr
u
it
m
en
t
fo
r
1
ad
d
it
io
n
al
m
o
n
th
u
p
to
th
e
IM
P
ex
p
ir
y
d
at
e,
in
o
rd
er
to
m
ax
im
is
e
th
e
p
o
w
er
o
f
th
e
st
u
d
y.
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
TABLE 4 Randomisation: deviations from protocol by intention to treat
Protocol deviation
Trial group
Probiotic (n= 650) Placebo (n= 660)
Randomisation > 48 hours’ postnatal age, n (%) 1 (0.2) 1 (0.2)
Gestational age < 23+0 weeks, n (%) 0 1 (0.2)
Gestational age ≥ 30+6 weeks, n (%) 2 (0.3) 1 (0.2)
TABLE 5 Data entry form retrieval rates
Form
Retrieval rate
Due Received (% of total due)
Consent form 1315 1314 (99.9)
Form 1: trial entry 1315 1314 (99.9)
Form 2: daily data collection 1315 1310 (99.6)
Form 3: clinical details of baby at transfer, discharge or death 2535 2530 (99.8)
Form 4: abdominal pathology 609 609 (100)
Form 5: SAE/SUSAR 2 2 (100)
Form 6: parental discontinuation or withdrawal 37 37 (100)
Total 7128 7116 (99.8)
Total randomised
(n = 1315)
Allocated to B breve BBG-001
(n = 654)
• Received B. breve BBG-001, 
   n = 649
• Received placebo, n = 0
• Did not receive any 
   intervention,a n = 5
Withdrawals: early permanent 
discontinuation of intervention
(n = 35)
Study withdrawals
(n = 4)c
• Parental request, n = 14
• Clinician recommendation, n = 21
Analysed
(n = 650)
Allocated to placebo
(n = 661)
• Received placebo, n = 656
• Received B. breve BBG-001,b n = 2
• Did not receive any 
   intervention,a n = 3
Withdrawals: early permanent 
discontinuation of intervention
(n = 41)
Study withdrawals
(n = 1)c
• Parental request, n = 14
• Clinician recommendation, n = 26
• No reason given, n = 1
Analysed
(n = 660)
FIGURE 4 Participant flow. a, Of eight babies who received no intervention, seven died within 7 days of birth and
one was transferred on the first day after birth to a hospital without the necessary approvals to administer the
intervention; b, Two babies were incorrectly allocated packs containing B. breve BBG-001 and received that
product throughout their course; c, Five sets of parents, four in the probiotic and one in the placebo group,
withdrew from the trial completely and also withdrew consent for the use of data already collected.
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Chapter 4 Final analysis
Baseline data
Maternal and baby characteristics were similar between the two groups (Tables 6 and 7). Nine per cent
of babies were born outside the recruiting centre and 26% were randomised within the first 24 hours.
The median age at which the first dose of intervention was administered was 44 hours.
Several of the highest recruiting hospitals are sited in multicultural inner-city areas: this is reflected in the
spread of ethnicity, with 57% of babies overall being born to white women, 20% to Afro-Caribbean
women and 12% to women whose families were from the Indian subcontinent.
Ninety-one per cent of the babies had been exposed to antenatal corticosteroid, 28% were born following
pregnancies with rupture of the placental membranes more than 24 hours previously and 36% had been
exposed to maternal antibiotics within 24 hours of birth.
The median gestational age was 28+0 weeks, 48% being born before 28 weeks. Mean birthweight was
1041 g, 49% being born at or below a birthweight of 1000 g.
Other early characteristics
Of 22 babies with major malformations, three in the probiotic and two in the placebo group died before
discharge from hospital.
There were 1281 (98%) babies who received enteral nutrition within the first 14 days, of whom 96%
received some maternal breast milk. In 48.5% of these, the maternal milk was augmented with either
donor breast or formula milk (Table 8). Of the 29 babies who received no milk in the first 14 days, 18 died,
13 in the probiotic group and five in the placebo group. Almost all of the babies received antibiotics in
the first 5 days after birth, and around 70% were given more antibiotic between day 6 and day 14.
In total, 10.8% received antacid; antacid administration was recorded because of the possibility that
raising the gastric pH would impact the microbiome.
Compliance
A total of 76 (5.8%) babies discontinued the intervention early, 28 at parental request and the others for
clinical indications. These include a small number of babies who in the early stages of the trial discontinued
the intervention early because they were transferred to a hospital that did not have the regulatory approvals
to administer the intervention.
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TABLE 6 Baseline data by intention to treat: maternal characteristics
Characteristic
Trial group
Probiotic (n= 650) Placebo (n= 660)
Ethnic group, n (n/N, %)
White 374 (57.8) 362 (55.4)
Indian 28 (4.3) 33 (5.0)
Pakistani 17 (2.6) 20 (3.0)
Bangladeshi 32 (4.9) 30 (4.6)
Black African 96 (14.8) 100 (15.3)
Black Caribbean 32 (4.9) 31 (4.7)
Other 68 (10.5) 77 (11.8)
Missing 3 7
Maternal (years)
Mean (SD) 30.6 (6.5) 30.9 (6.6)
Range 15–58 15–58
Missing 0 1
Antenatal steroid use, n (n/N, %)
Yes, started within 24 hours of birth 168 (26.1) 167 (25.5)
Yes, started over 24 hours before birth 412 (63.9) 440 (67.1)
None 65 (10.1) 49 (7.5)
Missing 5 4
Membrane rupture more than 24 hours before birth, n (n/N, %)
Yes 171 (27.2) 187 (29.1)
No 458 (72.8) 456 (70.9)
Missing 21 17
Chorioamnionitis diagnosed clinically within 24 hours of birth, n (n/N, %)
Yes 88 (14.4) 80 (13.0)
No 523 (85.6) 537 (87.0)
Missing 39 43
Maternal antibiotics within 24 hours of birth, n (n/N, %)
Yes 220 (36.5) 226 (36.1)
No 383 (63.5) 400 (63.9)
Missing 47 34
N= number reporting.
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TABLE 7 Baseline data by intention to treat: infant characteristics
Characteristic
Trial group
Probiotic (n= 650) Placebo (n= 660)
Postnatal age at randomisation (hours)
Median 35.3 35.4
IQR 23.8–43.3 23.4–43.6
Range 0.5–50.5 0.7–48.2
< 24 hours, n (%) 167 (25.7) 172 (26.1)
24 to ≤ 48 hours, n (%) 482 (74.2) 487 (73.8)
> 48 hours, n (%) 1 (0.2) 1 (0.2)
Gestational age at birth (weeks)
Median 28.0 28.0
IQR 26.1–29.4 26.1–29.6
Range 23.0–31.6 22.6–31.0
< 23 weeks, n (%) 0 1 (0.2)
23 to < 24 weeks, n (%) 20 (3.1) 17 (2.6)
24 to < 25 weeks, n (%) 60 (9.2) 60 (9.1)
25 to < 26 weeks, n (%) 69 (10.6) 73 (11.1)
26 to < 28 weeks, n (%) 166 (25.5) 168 (25.5)
28 to < 30 weeks, n (%) 217 (33.4) 219 (33.2)
≥ 30 weeks, n (%) 118 (18.2) 122 (18.5)
Sex
Male, n (%) 374 (57.5) 370 (56.1)
Female, n (%) 276 (42.5) 290 (43.9)
Babies born per pregnancy
Singleton, n (%) 457 (70.3) 459 (69.6)
Multiple, n (%) 193 (29.7) 201 (30.5)
If multiple, babies born, n (% of multiples)
1 2 (1.0) 0
2 167 (86.5) 175 (87.1)
3 19 (9.8) 23 (11.4)
4 5 (2.6) 3 (1.5)
Born in enrolling hospital, n (n/N, %)
Yes 589 (90.6) 603 (91.5)
No 61 (9.4) 56 (8.5)
Missing 0 1
Mode of delivery, n (n/N%, )
Vaginal birth 309 (47.5) 310 (47.0)
Caesarean before labour onset 221 (34.0) 204 (31.0)
Caesarean after labour onset 120 (18.5) 145 (22.0)
Missing 0 1
continued
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TABLE 7 Baseline data by intention to treat: infant characteristics (continued )
Characteristic
Trial group
Probiotic (n= 650) Placebo (n= 660)
Forceps or ventouse used, n (n/N, %)
Yes 13 (2.0) 16 (2.5)
No 634 (98.0) 638 (97.6)
Missing 3 6
Main cause of preterm birth, n (n/N, %)
Prelabour rupture of membranes 184 (28.5) 182 (27.7)
Preterm labour 245 (37.9) 276 (42.0)
Antepartum haemorrhage 54 (8.4) 63 (9.6)
Pregnancy-induced hypertension 54 (8.4) 34 (5.2)
Other maternal illness 66 (10.2) 54 (8.2)
Poor fetal growth (mother well) 43 (6.7) 48 (7.3)
Missing 4 3
Birthweight (g)
n 650 660
Mean (SD) 1039 (311.7) 1043 (317.0)
Range 450–2200 475–1935
Birthweight ≤ 1000 g, n (%) 317 (48.8) 327 (49.5)
Birthweight > 1000 g, n (%) 333 (51.2) 333 (50.5)
Birthweight z-score
n 649 657
Mean (SD) –0.43 (1.04) –0.42 (1.05)
Range –3.7 to 3.9 –3.7 to 4.1
Missing 1a 3a
Heart rate > 100 b.p.m. 5 minutes after birth, n (n/N, %)
Yes 599 (92.4) 593 (90.4)
No 49 (7.6) 63 (9.6)
Missing 2 4
Apgar score 5 minutes after birth, n (n/N, %)
0–3 25 (3.9) 15 (2.3)
4–6 86 (13.5) 96 (15.0)
7–10 524 (82.5) 531 (82.7)
Missing 15 18
CRIB II71
n 606 622
Mean (SD) 8.9 (3.5) 8.8 (3.4)
Range 2–20 1–19
Missing 44 38
b.p.m., beats per minute; CRIB, Clinical Risk Index for Babies; IQR, interquartile range.
a Despite complete data for gestational ages and birthweights there are four missing values for birthweight z-scores.
This is because four of the babies were below the reference range of age for any given weight of –0.326 to 23 weeks.
N= number reporting, if N is not specified the data are complete with no missing items.
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TABLE 8 Other early data collected post-randomisation by intention to treat
Characteristic
Trial group
Probiotic (n= 650) Placebo (n= 660)
Age at first dose of intervention (hours)
N 633 638
Median age (hours) 43.9 44.3
IQR 31.1–52.1 32.2–51.1
Congenital malformationsa
Yes, n/N (%) 30 (4.6) 37 (5.6)
No, n/N (%) 620 (95.4) 622 (94.4)
Missing, n 0 1
If Yes
Minor,b n (% of congenital malformations) 19 (63.3) 24 (68.6)
Major,b n (% of congenital malformations) 11 (36.7) 11 (31.4)
Missing, n 0 2
Enteral feeding in the first 14 days,c postnatal age at first feed (days)
Number fed within 14 days of birth 634 647
Mean age (SD) 3.2 (1.9) 3.2 (1.9)
Median age (days) 3 3
IQR 2–4 2–4
Range 1–14 1–14
Type of milk received (0–14 days)
Any maternal breast milk, n (% of those fed in first 14 days) 602 (92.6) 625 (94.7)
Any donor breast milk, n (% of those fed in first 14 days) 131 (20.2) 139 (21.1)
Any formula, n (% of those fed in first 14 days) 223 (34.3) 226 (34.2)
Maternal breast milk only (0–14 days)
Yes, n (%) 300 (46.2) 306 (46.4)
No, n (%) 350 (53.8) 354 (53.6)
Antacids and antibiotic use (0–14 days)d
Any antacid given, n (%) 64 (9.9) 77 (11.7)
Antibiotics given in first 5 days, n (%) 647 (99.5) 651 (98.6)
Antibiotics given between day 6 and day 14, n (%) 452 (69.5) 471 (71.4)
IQR, interquartile range.
a All babies with gastrointestinal anomalies and potentially lethal anomalies of other organs systems apparent within
48 hours of birth were ineligible for recruitment. Babies with other congenital malformations becoming apparent later
were followed until death or discharge from hospital.
b Malformations were classified as major only if they were life-threatening in infancy or might affect the health of the
baby while on the neonatal unit in such a way as to interfere with the conduct of the trial.
c Details of early feeds were not collected if the start of feeding was deferred beyond day 14.
d Details of medications were not collected beyond day 14.
N= number reporting, if N is not specified, the data are complete with no missing items.
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On average, infants received around 87% of the recommended doses between randomisation and
36 weeks’ postmenstrual age or death if sooner (Table 9).
The number of those born at higher gestation age falling below the ‘whisker’ on Figure 5 is largely
because of babies being discharged from hospital before 36 weeks’ postmenstrual age. It is thought likely
that the wider range of compliance at extremely low gestation age is because of those babies having
more episodes when the clinicians chose to omit doses, although the effect is only apparent in the
probiotic and not the placebo group.
Quality of the interventions
No organisms other than B. breve BBG-001 were grown from any of the sachets returned to the laboratory
at Barts Health NHS Trust.
The number of viable B. breve BBG-001 in the returned sachets fell as predicted during the recruitment
period (Figure 6). The average number of viable organisms in the sachets measured in November 2013
(1 month after the final dose of intervention was given in the trial) was 1.5 × 108 CFUs with a range from
7.0 × 107 to 1.5 × 108 CFUs. The lowest count remained above the level of 6.7 × 107 CFUs that had been
agreed with the MHRA to be the low threshold for dosage.
Primary outcomes by intention to treat
There was no evidence that administration of the probiotic had a beneficial effect on any of the primary
outcomes. The proportion of infants who had an episode of NEC Bell stage 2 or 3 was 10.0% in the
probiotic group, compared with 9.4% in the placebo group (adjusted RR 0.93, 95% CI 0.68 to 1.27);
the corresponding figures for late-onset sepsis were 11.7% and 11.2% (adjusted RR 0.97, 95% CI
0.73 to 1.29) and for death were 8.5% and 8.3% (adjusted RR 0.93, 95% CI 0.67 to 1.30) (Table 10).
TABLE 9 Compliance with intervention by intention to treat
Trial group
Probiotic (n= 650) Placebo (n= 660)
Permanent early discontinuation, n (%) 35 (5.4) 41 (6.2)
Reason for permanent early discontinuation, n (n/N, %)
Parental request 14 (2.2) 14 (2.1)
Clinician recommendation 21 (3.2) 26 (3.9)
Missing 0 1
Per cent recommended dosesa taken between randomisation
and 36 weeks’ postmenstrual age, n
597 608
Mean (SD), % 86.7 (21.3) 87.8 (19.5)
Missing, % 31 34
Data unreliable and set to missing,b % 22 18
a The number of recommended doses is based on the number of days between randomisation and 36 weeks’
postmenstrual age or death if sooner. Proportions are > 100% if more doses than recommended were given.
b If the reported duration of ‘temporary’ interruption of administration of the intervention was greater than the total of
recommended doses we concluded that the data were unreliable and both the temporary interruption and percentage
of recommended doses taken were set to missing.
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FIGURE 5 Adherence to trial intervention by allocation, gestational age and intention to treat for (a) probiotic
group; and (b) placebo group. Box and whisker plot by gestational age and percentage of recommended doses
that were given. The whiskers represent the adjacent values (1.5 × interquartile range).
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
10
.0 9.
8
9.
6
9.
4
9.
2
9.
0
Log
10
 CFU
8.
8
8.
6
8.
4
8.
2
8.
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
M
o
n
th
s 
si
n
ce
 m
an
u
fa
ct
u
re
 a
n
d
 a
ct
u
al
 d
at
es
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
September 2009
October 2009
November 2009
December 2009
January 2010
February 2010
March 2010
April 2010
May 2010
June 2010
July 2010
August 2010
September 2010
October 2010
November 2010
December 2010
January 2011
February 2011
March 2011
April 2011
May 2011
June 2011
July 2011
August 2011
September 2011
October 2011
November 2011
December 2011
January 2012
February 2012
March 2012
April 2012
May 2012
June 2012
July 2012
August 2012
September 2012
October 2012
September 2013
October 2013
November 2012
December 2012
January 2013
February 2013
March 2013
April 2013
May 2013
June 2013
July 2013
August 2013
B
at
ch
 1
B
at
ch
 2
B
at
ch
 B
B
G
-0
01
Es
ti
m
at
ed
 s
in
g
le
 
d
o
se
 u
se
d
 in
 
K
it
aj
m
a 
et
 a
l.4
3
Lo
w
er
 c
u
t-
o
ff
 
p
o
in
t 
p
er
 s
ac
h
et
FI
G
U
R
E
6
V
ia
b
ili
ty
o
f
B
.b
re
ve
B
B
G
-0
01
in
re
tu
rn
ed
sa
ch
et
s
o
ve
r
th
e
re
cr
u
it
m
en
t
p
er
io
d
.
Th
e
y-
ax
is
re
p
re
se
n
ts
th
e
co
u
n
t
o
f
B
.
b
re
ve
B
B
G
-0
01
ex
p
re
ss
ed
in
lo
g
10
C
FU
s.
Th
e
x-
ax
is
re
p
re
se
n
ts
ac
tu
al
d
at
e
fo
r
th
e
b
at
ch
o
f
B
.b
re
ve
B
B
G
-0
01
u
se
d
in
th
e
Pi
PS
tr
ia
la
n
d
ti
m
e
in
m
o
n
th
s
si
n
ce
m
an
u
fa
ct
u
re
fo
r
al
lb
at
ch
es
.T
h
e
g
re
en
an
d
b
la
ck
lin
es
w
er
e
p
ro
vi
d
ed
b
y
th
e
m
an
u
fa
ct
u
re
r
an
d
re
la
te
to
tw
o
ea
rl
ie
r
b
at
ch
es
o
f
th
e
p
ro
d
u
ct
.T
h
e
co
u
n
ts
ar
e
p
er
sa
ch
et
an
d
ex
te
n
d
fo
r
42
m
o
n
th
s
af
te
r
m
an
u
fa
ct
u
re
.T
h
e
b
lu
e
lin
e
is
th
e
co
u
n
t
p
er
d
o
se
o
f
B
.b
re
ve
B
B
G
-0
0,
1
as
m
ad
e
u
p
fo
r
th
e
Pi
PS
tr
ia
l.
Th
e
b
lu
e
tr
ia
n
g
le
s
re
p
re
se
n
t
th
e
m
ea
n
o
f
al
lm
ea
su
re
m
en
ts
m
ad
e
si
n
ce
th
e
p
re
vi
o
u
s
tr
ia
n
g
le
.
Th
e
co
n
ti
n
u
o
u
s
h
o
ri
zo
n
ta
l
lin
e
at
ar
o
u
n
d
8.
7
lo
g
10
-C
FU
s
re
p
re
se
n
ts
th
e
es
ti
m
at
ed
si
n
g
le
d
o
se
u
se
d
in
th
e
tr
ia
l
o
f
K
it
aj
im
a
et
al
.4
3
Th
e
h
o
ri
zo
n
ta
l
in
te
rr
u
p
te
d
lin
e
at
8.
3
lo
g
10
-C
FU
s
re
p
re
se
n
ts
th
e
lo
w
er
cu
t-
o
ff
p
o
in
t
p
er
sa
ch
et
o
f
th
e
b
at
ch
o
f
B
.b
re
ve
B
B
G
-0
01
p
ro
vi
d
ed
b
y
th
e
m
an
u
fa
ct
u
re
r
fo
r
th
e
Pi
PS
tr
ia
l.
W
h
en
p
re
p
ar
ed
as
fo
r
th
e
tr
ia
l
th
is
eq
u
at
es
to
1
m
l
p
ro
vi
d
in
g
a
d
o
se
o
f
6.
7
×
10
7
o
r
7.
8
lo
g
10
-C
FU
s.
FINAL ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Subgroup analyses of primary outcomes by intention to treat
The prevalence of infection associated with probiotic administration was reduced (from 7.3% to 2.8%) in
the subgroup born at 28 and 29 weeks (adjusted RR 0.39, 99% CI 0.16 to 0.96). There were no other
differences for the prespecified subgroup analyses for the three primary outcomes or for exploratory
analyses for subgroups with birthweight > 1 kg versus < 1 kg (Figure 7).
Severity of necrotising enterocolitis
Prespecified exploratory analyses showed no evidence of any differences in the age at onset of NEC
(median postnatal age 30 weeks in both groups) or in severity (62% of cases categorised as stage 3 in
probiotic vs. 68% placebo). The primary causes of death were also similar, with 21 of 54 deaths in the
probiotic group and 24 of 56 in the placebo group being attributed either to late-onset sepsis or to NEC
(Table 11).
Secondary outcomes by intention to treat
There was also no evidence of benefit for any of the secondary outcomes including other measures of
late-onset sepsis (Table 12); the proportion of infants with any positive blood culture after 72 hours was
28.6% in the probiotic group and 31.2% in the placebo group. The range of infecting bacteria was similar
between the groups, with Enterobacteriaceae or staphylococci being identified in the majority of cases.
There were three bloodstream infections attributable to antibiotic-resistant bacteria in the probiotic group
and eight in the placebo group.
Infections that were not bloodstream infections were similar between the groups and there were no
reports of growth of Bifidobacterium from any normally sterile site.
Rates of other major neonatal morbidities, administration of antimicrobials, time to establish full enteral
feeds, growth up to 36 weeks’ postmenstrual age and length of stay were similar between the groups
(see Table 12).
The Kaplan–Meier plot of time to first full feed at 150ml of milk/kg/day is a Figure 8.
One or both of the stool samples collected from 38 (out of 611, 6.2%) infants in the probiotic and
35 (out of 619, 5.7%) in the placebo group were colonised with antibiotic-resistant bacteria (Table 13).
Stool colonisation by Bifidobacterium breve by intention to treat
Stools were received at the microbiology laboratory at Barts Health NHS Trust from 1186 (94%) of the
1266 babies still alive at 2 weeks’ postnatal age and from 1043 (83%) of the 1235 babies still alive at
36 weeks’ postmenstrual age.
TABLE 10 Primary outcomes by intention to treat
Primary analysis
Trial group
Adjusteda RR (95% CI)Probiotic (n= 650), n (%) Placebo (n= 660), n (%)
Late-onset sepsisb 73 (11.2) 77 (11.7) 0.97 (0.73 to 1.29)
NECc 61 (9.4) 66 (10.0) 0.93 (0.68 to 1.27)
Death before discharge
from hospital
54 (8.3) 56 (8.5) 0.93 (0.67 to 1.30)
a Adjusted for sex, gestational age at birth and randomisation within 24 hours of birth. Centre was excluded, as the
model did not converge. Allowances for correlations between multiple births are accounted for.
b Late-onset sepsis is defined as bloodstream infection with non-skin commensals after 72 hours’ postnatal age and before
46 weeks’ postmenstrual age.
c Necrotising enterocolitis Bell stage 2 or 3.
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TABLE 11 Prespecified exploratory analyses of NEC, spontaneous intestinal perforation and primary cause of death
Outcome
Trial group
Adjusteda RR (99% CI)
Probiotic (n= 650),
n (%)
Placebo (n= 660),
n (%)
NEC Bell stage 3 38 (5.9) 45 (6.8) 0.85 (0.51 to 1.41)
Surgery for NEC stage ≥ 2 35 (5.4) 39 (5.9) 0.89 (0.53 to 1.51)
Death attributed to NEC stage ≥ 2 9 (1.4) 14 (2.1) 0.62 (0.21 to 1.84)
Postmenstrual age (weeks) at onset of NEC
stage ≥ 2, median (IQR)
30.0 (27.9 to 32.6) 30.1 (28.0 to 32.1) –0.71 (–2.4 to 1.0)
Spontaneous intestinal perforation 7 (1.1) 4 (0.6) 1.30 (0.71 to 2.3)
Deaths attributed to infection, n (%) 12 (1.8) 10 (1.5) 1.10 (0.66 to 1.80)
IQR, interquartile range.
a Adjusted for sex, gestational age at birth and randomisation within 24 hours of birth. Centre was excluded, as the
model did not converge. Allowances for correlations between multiple births are accounted for.
TABLE 12 Secondary outcomes by intention to treat
Secondary outcomes
Trial group
Adjusteda RR (99% CI)
Probiotic (n= 650),
n (%)
Placebo (n= 660),
n (%)
Late-onset sepsisb, NECc or death at
discharge home
143 (22.0) 147 (22.3) 0.99 (0.79 to 1.25)
Late-onset sepsis-related and microbiological outcomes
Positive blood culture for skin commensal 141 (21.7) 161 (24.4) 0.88 (0.69 to 1.13)
Any blood culture taken after 72 hours 490 (75.4) 519 (78.6) 0.97 (0.92 to 1.02)
Number of blood cultures per infant after
72 hours, median (IQR)
2 (1 to 4) 2 (1 to 5) 0 (0–0)
Bloodstream infection by organism
Enterobacteriaceae 23 (3.5) 29 (4.4) 0.80 (0.41 to 1.59)
Enterococcus 13 (2.0) 14 (2.1) 0.92 (0.35 to 2.43)
Staphylococcus 21 (3.2) 17 (2.6) 1.26 (0.56 to 2.82)
Fungi 5 (0.8) 5 (0.8) 1.00 (0.20 to 5.06)
Other non-skin commensals 22 (3.4) 22 (3.3) 0.93 (0.44 to 1.96)
Antibiotic-resistant bloodstream infection
MRSA 0 3 (0.5) Too few data
VRE 1 (0.2) 0 Too few data
ESBL-producing Gram-negative bacteria 1 (0.2) 5 (0.8) Too few data
Gentamicin resistant 1 (0.2) 0 Too few data
continued
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TABLE 12 Secondary outcomes by intention to treat (continued )
Secondary outcomes
Trial group
Adjusteda RR (99% CI)
Probiotic (n= 650),
n (%)
Placebo (n= 660),
n (%)
Isolates of organisms from other normally sterile sites
Suprapubic urine 1 (0.2) 1 (0.2) Too few data
Cerebrospinal fluid 5 (0.8) 6 (0.9) 0.83 (0.18 to 3.80)
Pleural cavity 1 (0.2) 0 Too few data
Peritoneum 13 (2.0) 10 (1.5) 1.31 (0.45 to 3.84)
Other (joint fluid) 0 1 (0.2) Too few data
B. breve BBG-001 from any normally
sterile site
0 0 Too few data
Total days of antibiotics after 72 hours,
median (IQR) [range]
10 (4 to 23)
[0 to130]
11 (4–24)
[0 to 202]
0 (–2 to 1)
Total days of antifungals after 72 hours,
median (IQR) [range]
0 (0 to 0) [0 to 154] 0 (0 to 0) [0 to 79] 0 (0 to 0)
Enteral feeding and growth
n 649 660
Reached full feeds, n (%) 613 (94.5) 619 (93.8) 0.91 (0.79 to 1.06)d
Died before reaching full feeds, n (%) 32 (4.9) 37 (5.6)
Missing, n 1 0
Postnatal age at first full feed, (150ml of milk/kg/day), days
Median 14 14
99% CI 13 to 16 13 to 16
IQR 10 to 22 10 to 22
Change in weight z-score (from baseline to 36 weeks’ postmenstrual age)
n 648 657
Mean (SD) –1.33 (0.93) –1.38 (0.92) 0.03 (–0.08 to 0.15)
Range –4.62 to 1.8 –6.76 to 2.69
Other morbidities
Survivors to 36 weeks’ postmenstrual age, n 595 604
Bronchopulmonary dysplasia (any O2 at
36 weeks’ postmenstrual age), n (n/N, %)
239 (40.2) 223 (36.9) 1.02 (0.87 to 1.20)
Severe bronchopulmonary dysplasia at
36 weeks’ postmenstrual agee
87 (14.6) 73 (12.1) 1.13 (0.80 to 1.60)
n 646 657
Hydrocephalus and/or porencephaly and/or
periventricular leucomalacia noted at any
timef
46 (7.1) 37 (5.6) 1.23 (0.72 to 2.12)
n 600 605
Worst stage of retinopathy of prematurity
≥ stage 3 in either eye
23 (3.8) 25 (4.1) 0.91 (0.44 to 1.88)
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TABLE 12 Secondary outcomes by intention to treat (continued )
Secondary outcomes
Trial group
Adjusteda RR (99% CI)
Probiotic (n= 650),
n (%)
Placebo (n= 660),
n (%)
Length of stay
n 647 657
Total length of hospital stay (days),
median (IQR)
68 (48 to 98) 66 (46 to 95) 1 (–4 to 6)
n 649 658
Intensive care stay (days), median (IQR) 10 (5 to 32) 12 (5 to 32) 0 (–1 to 1)
High-dependency unit stay (days),
median (IQR)
20 (6 to 34) 17 (5 to 33) 1 (–1 to 3)
IQR, interquartile range.
a Adjusted for sex, gestational age at birth and randomisation within 24 hours of birth (except for fungi, urine and
cerebrospinal fluid, which are not adjusted for gestational age). Centre was excluded as the model did not converge.
Allowances for correlations between multiple births are accounted for.
b Late-onset sepsis is defined as bloodstream infection with non-skin commensals after 72 hours’ postnatal age and before
46 weeks’ postmenstrual age.
c Necrotising enterocolitis Bell stage 2 or 3.
d Hazard ratio.
e Severe bronchopulmonary dysplasia was defined as still receiving mechanical ventilatory support or, if breathing
spontaneously, still receiving more than 0.1 l/minute low-flow oxygen or 30% or higher supplementary oxygen.72
f An additional 35 babies (11 in the probiotic group and 24 in the placebo group) had reports of haemorrhagic
parenchymal infarcts but never progressed to have reports of hydrocephalus, porencephaly or periventricular
leucomalacia, of these nine in the probiotic and 14 in the placebo group died before discharge from hospital.
HR 0.91, 99% CI 0.79 to 1.06
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FIGURE 8 Kaplan–Meier plot of time to first full feed at 150ml of milk/kg/day by intention to treat.
HR, hazard ratio.
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
By 2 weeks’ postnatal age, B. breve BBG-001 was detected by culture in 73.8% of the stool samples
available from babies in the probiotic group and in 20.5% of those from the placebo group, rising to
83.6% and 48.7%, respectively, at 36 weeks’ postnatal age (see Table 13).
At 2 weeks’ postnatal age, 1007 samples contained sufficient stool to also test for the presence of
B. breve BBG-001 using PCR. Of the 123 samples from babies in the probiotic group that were culture
negative, 69 (56.1%) were positive by PCR, and of the 405 negative samples in the placebo group
94 (24.0%) were positive. A total of 85% of babies in the probiotic and 37% in the placebo group had
B. breve BBG-001 detected in their stools using either culture or PCR (see Table 13).
Of the 504 babies in the probiotic group who had stools cultured at both 2 weeks’ postnatal and 36 weeks’
postmenstrual age, 54 (10.7%) were positive for B. breve BBG-001 on only the first occasion, 104 (20.6%)
were positive only on the second and 317 (62.9%) on both occasions. In the placebo group, 23 of 495 (4.6%)
were positive on only the first occasion, 169 (34.1%) on only the second and 75 (15.2%) on both occasions.
Total colonisation rates by culture were monitored by site during recruitment and ranged at 2 weeks’
postnatal age from 37.5% to 80.3% (Table 14). During the course of the trial those hospitals with higher
colonisation rates were often those with smaller numbers of babies and at no time were there hospitals
that were clearly high outliers so as to trigger additional training from the trial research nurses.
TABLE 13 Secondary outcomes by intention to treat: stool microbiology
Secondary outcome
Trial group
Adjusteda RR (99% CI)
Probiotic (n= 650),
n (%)
Placebo (n= 660),
n (%)
Stool culture at 2 weeks’ postnatal age, 1266 infants alive, 1186 (94%) stool samples received
B. breve BBG-001, n (% of received) 436 (73.8) 122 (20.5) 3.51 (2.83 to 4.34)
MRSA 1 (0.2) 2 (0.3) Too few data
VRE 0 1 (0.2) Too few data
ESBL-producing Gram-negative bacteria 18 (3.0) 20 (3.4) 0.76 (0.36 to 1.61)
Stool PCR at 2 weeks’ postnatal age
PCR positive, n (% of tested) 416 (84) 177 (35) 2.42 (2.06 to 2.85)
B. breve BBG-001 positive by culture or PCR 505 (85) 219 (37) 2.30 (1.99 to 2.66)
Stool culture at 36 weeks’ postmenstrual age, 1245 infants alive, 1043 (84%) stool samples received
B. breve BBG-001, n (% of received) 438 (83.6) 253 (48.7) 1.69 (1.50 to 1.91)
MRSA 1 (0.2) 0 Too few data
VRE 3 (0.6) 1 (0.2) 2.97 (0.15 to 57.67)
ESBL-producing Gram-negative bacteria 19 (3.6) 18 (3.5) 0.98 (0.44 to 2.18)
a Adjusted for sex, gestational age at birth and randomisation within 24 hours of birth. Centre was excluded, as the
model did not converge. Allowances for correlations between multiple births are accounted for.
Note
Of the 1186 stools received at 2 weeks’ postnatal age there was sufficient material available to perform PCR to detect
B. breve BBG-001 on 1007.
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Determinants of colonisation
The results of the analysis of determinants of colonisation at 2 weeks in the probiotic group are presented
in Table 15. In the final model, only increasing gestational age in weeks was statistically significantly
associated with increased colonisation (OR 1.36; p< 0.0001), and the administration of any antibiotic
beyond the fifth day after birth was significantly associated with less colonisation (OR 0.26; p= 0.027).
Administration to the mother of antibiotic in the 24 hours preceding birth was marginally associated with
an increased OR (1.76; p= 0.0506) and increasing age in days at the start of enteral milk feeds with
decreased colonisation (OR 0.90; p= 0.0725).
Secondary analysis by colonisation with Bifidobacterium breve at 2 weeks’
postnatal age
At 2 weeks’ postnatal age, stool colonisation data were available for 1186 babies in 724 (61.0%),
of whom B. breve BBG-001 was detected either by culture or by PCR.
TABLE 14 Total number of babies with B. breve BBG-001 detected in stool either by culture or PCR at 2 weeks’
postnatal age by hospital site where the baby was recruited
Enrolling centre
Colonisation with B. breve BBG-001, n (% at site)
Yes (n= 724) No (n= 462)
Homerton University Hospital 142 (63.7) 81 (36.3)
University College Hospital 51 (57.3) 38 (42.7)
St Peter’s Hospital, Chertsey 54 (60.7) 35 (39.3)
St Thomas’ Hospital, London 46 (54.8) 38 (45.2)
John Radcliffe Hospital 34 (50.0) 34 (50.0)
Medway Maritime Hospital 49 (68.1) 23 (31.9)
The Royal London Hospital 35 (54.7) 29 (45.3)
St George’s Hospital, London 35 (66.0) 18 (34.0)
Newham University Hospital 49 (80.3) 12 (19.7)
William Harvey Hospital, Ashford 33 (58.9) 23 (41.1)
Royal Sussex County Hospital 9 (37.5) 15 (62.5)
Queen’s Hospital, Romford 28 (57.1) 21 (42.9)
Tunbridge Wells Hospital at Pembury 19 (57.6) 14 (42.4)
Luton and Dunstable Hospital 17 (54.8) 14 (45.2)
Watford General Hospital 17 (63.0) 10 (37.0)
Barnet Hospital 18 (62.1) 11 (37.9)
University Hospital Lewisham 14 (66.7) 7 (33.3)
Whipps Cross Hospital 18 (72.0) 7 (28.0)
King’s College Hospital 15 (68.2) 7 (31.8)
Southend University Hospital 11 (61.1) 7 (38.9)
North Middlesex University Hospital 12 (70.6) 5 (29.4)
Basildon Hospital 8 (72.7) 3 (27.3)
Croydon University Hospital 5 (45.5) 6 (54.6)
Whittington Hospital 5 (55.6) 4 (44.4)
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TABLE 15 Significance of determinants of successful colonisation with B. breve BBG-001 at 2 weeks’ postnatal age
for babies who were randomised to and given probiotic from whom stool samples were received (n= 591)
Characteristic
Single factor
models Model 2 Model 3
Final
model
Postnatal age at first dose (hours) OR 0.99
(p= 0.0659)
Gestational age at birth (weeks) OR 1.42
(p< 0.0001a)
OR 1.33
(p< 0.0001)
OR 1.40
(p< 0.0001)
OR 1.36
(p< 0.0001)
Birthweight (kg) OR 1.00b
(p< 0.0001)
Apgar score at 5 minutes OR 1.15
(p= 0.0122)
Day of first feed OR 0.81
(p< 0.0001)
OR 0.90
(p= 0.0725)
Sex (male, female) OR 1.40
(p= 0.1614)
Multiple birth (single/multiple) OR 0.98
(p= 0.9209)
Ethnic group p= 0.4881
White vs. Indian OR 0.73
White vs. Pakistani OR 2.91
White vs. Bangladeshi OR 2.19
White vs. black African OR 0.81
White vs. black Caribbean OR 1.18
White vs. other OR 2.00
Antenatal steroids prior to birth (yes/no) OR 1.00
(p= 0.9913)
Membrane rupture > 24 hours before birth (yes/no) OR 1.16
(p= 0.5808)
Antibiotics in 24 hours before birth (yes/no) OR 1.44
(p= 0.1635)
OR 1.94
(p= 0.0199)
OR 1.76
(p= 0.0506)
Chorioamnionitis in 24 hours before birth (yes/no) OR 0.80
(p= 0.5010)
Delivery mode (caesarean/vaginal delivery) OR 0.62
(p= 0.0434)
Formula and breast milk (day 1–14) OR 2.21
(p= 0.0056)
Formula only (day 1–14) OR 1.29
(p= 0.7415)
Breast milk only (day 1–14) OR 0.52
(p= 0.0151)
Antacids (day 1–14) OR 1.24
(p= 0.6096)
Antibiotics (day 6–14) OR 0.14
(p< 0.0001)
OR 0.21
(p= 0.0004)
OR 0.24
(p= 0.0014)
OR 0.26
(p= 0.0027)
Variables were added to the model taking the variable with the lowest p-value first. All variables were retested, one by one,
in the new model and the next variable was selected using the new lowest p-value. The final model was reached when no
remaining potential variable had a p-value of < 0.1 and no existing variable had a p-value of > 0.2.
a Lowest p-value.
b > 1.00.
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Baseline data by colonisation
The baseline characteristics of mothers and babies, together with early clinical data collected after
randomisation by colonisation status at 2 weeks are presented in Tables 16–18 and show few differences
between the groups other than an under-representation among the colonised babies of those who had
received only maternal breast milk and of those who had received any antibiotic after the fifth day of life.
TABLE 16 Baseline data by colonisation status at 2 weeks’ postnatal age: maternal characteristics
Characteristic
Colonisation with B. breve BBG-001
Yes (n= 724) No (n= 462)
Ethnic group
White, n (%col, %row) 407 (56.5, 60.1) 270 (58.7, 39.9)
Indian, n (%col, %row) 31 (4.3, 57.4) 23 (5.0, 42.6)
Pakistani, n (%col, %row) 26 (3.6, 81.3) 6 (1.3, 18.8)
Bangladeshi, n (%col, %row) 38 (5.3, 70.4) 16 (3.5, 29.6)
Black African, n (%col, %row) 99 (13.8, 55.9) 78 (17.0, 44.1)
Black Caribbean, n (%col, %row) 39 (5.4, 68.4) 18 (3.9, 31.6)
Other, n (%col, %row) 80 (11.1, 62.0) 49 (10.7, 38.0)
Missing, n 4 2
Mother’s age (years)
n 724 461
Mean (SD) 30.7 (6.5) 31.1 (6.62)
Minimum to maximum 15 to 58 16 to 58
Missing 0 1
Antenatal steroid use
Yes, started within 24 hours of birth, n (%col, %row) 177 (24.6, 57.8) 129 (28.2, 42.2)
Yes, started over 24 hours before birth, n (%col, %row) 476 (66.2, 61.6) 297 (64.9, 38.4)
None, n (%col, %row) 66 (9.2, 67.4) 32 (7.0, 32.7)
Missing, n 5 4
Membrane rupture more than 24 hours before birth
Yes, n (%col, %row) 193 (27.4, 59.2) 133 (29.8, 40.8)
No, n (%col, %row) 511 (72.6, 61.9) 314 (70.3, 38.1)
Missing, n 20 15
Chorioamnionitis diagnosed clinically within 24 hours of birth
Yes, n (%col, %row) 87 (12.9, 58.0) 63 (14.6, 42.0)
No, n (%col, %row) 588 (87.1, 61.4) 370 (85.5, 38.6)
Missing, n 49 29
Antibiotics in 24 hours before birth
Yes, n (%col, %row) 251 (37.1, 60.9) 161 (36.7, 39.1)
No, n (%col, %row) 426 (62.9, 60.5) 278 (63.3, 39.5)
Missing, n 47 23
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TABLE 17 Baseline data by colonisation status at 2 weeks’ postnatal age: infant characteristics
Characteristic
Colonisation with B. breve BBG-001
Yes (n= 724) No (n= 462)
Postnatal age at randomisation (hours)
n 724 462
Median 35.2 35.0
IQR 22.9 to 43.5 24.0 to 43.7
Range 0.5 to 48.0 1.0 to 48.2
≤ 24 hours, n (%col, %row) 201 (27.8, 63.6) 115 (24.9, 36.4)
24 to < 48 hours, n (%col, %row) 523 (72.2, 60.2) 346 (74.9, 39.8)
> 48 hours, n (%col, %row) 0 1 (0.2, 100)
Gestational age at birth (weeks)
n 724 462
Median 28.4 27.6
IQR 26.7 to 29.7 25.7 to 29.1
Range 23 to 31.6 22.6 to 30.9
< 23 weeks, n (%col, %row) 0 1 (0.2, 100)
23 to < 24 weeks, n (%col, %row) 13 (1.8, 43.3) 17 (3.7, 56.7)
24 to < 25 weeks, n (%col, %row) 47 (6.5, 48.0) 51 (11.0, 52.0)
25 to < 26 weeks, n (%col, %row) 70 (9.7, 54.3) 59 (12.8, 45.7)
26 to < 28 weeks, n (%col, %row) 172 (23.8, 57.7) 126 (27.3, 42.3)
28 to < 30 weeks, n (%col, %row) 272 (37.6, 66.7) 136 (29.4, 33.3)
≥ 30 weeks, n (%col, %row) 150 (20.7, 67.6) 72 (15.6, 32.4)
Sex
Male, n (%col, %row) 401 (55.4, 59.9) 268 (58.0, 40.1)
Female, n (%col, %row) 323 (44.6, 62.5) 194 (42.0, 37.5)
Babies born per pregnancy
Singleton, n (%col, %row) 496 (68.5, 59.5) 338 (73.2, 40.5)
Multiple, n (%col, %row) 228 (31.5, 64.8) 124 (26.8, 35.2)
If multiple, babies born, n (%col, %row)
1 2 (0.9, 100) 0
2 194 (85.1, 64.5) 107 (86.3, 35.6)
3 26 (11.4, 63.4) 15 (12.1, 36.6)
4 6 (2.6, 75.0) 2 (1.6, 25.0)
Born in enrolling hospital, n (%col, %row)
Yes 667 (92.1, 61.3) 421 (91.1, 38.7)
No 57 (7.9, 58.2) 41 (8.9, 41.8)
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TABLE 17 Baseline data by colonisation status at 2 weeks’ postnatal age: infant characteristics (continued )
Characteristic
Colonisation with B. breve BBG-001
Yes (n= 724) No (n= 462)
Mode of delivery
Vaginal birth, n (%col, %row) 332 (45.9, 60.4) 218 (47.3, 39.6)
Caesarean before labour onset, n (%col, %row) 240 (33.2, 62.8) 142 (30.8, 37.2)
Caesarean after labour onset, n (%col, %row) 152 (21.0, 60.1) 101 (21.9, 39.9)
Missing, n 0 1
Forceps or ventouse used
Yes, n (%col, %row) 18 (2.5, 66.7) 9 (2.0, 33.3)
No, n (%col, %row) 704 (97.5, 61.1) 448 (98.0, 38.9)
Missing, n 2 5
Main cause of preterm birth
Prelabour rupture of membranes, n (%col, %row) 211 (29.3, 62.2) 128 (27.8, 37.8)
Preterm labour, n (%col, %row) 275 (38.2, 59.4) 188 (40.9, 40.6)
Antepartum haemorrhage, n (%col, %row) 69 (9.6, 63.9) 39 (8.5, 36.1)
Pregnancy-induced hypertension, n (%col, %row) 51 (7.1, 67.1) 25 (5.4, 32.9)
Other maternal illness, n (%col, %row) 68 (9.4, 62.4) 41 (8.9, 37.6)
Poor fetal growth (mother well), n (%col, %row) 46 (6.4, 54.1) 39 (8.5, 45.9)
Missing, n 4 2
Birthweight (g)
n 724 462
Mean (SD) 1084 (312.4) 1000 (304.9)
Range 450 to 1935 475 to 1845
Birthweight ≤ 1000 g, n (%col, %row) 309 (42.7, 55.0) 253 (54.8, 45.0)
Birthweight > 1000 g, n (%col, %row) 415 (57.3, 66.5) 209 (45.2, 33.5)
Birthweight z-scorea
n 722 460
Mean (SD) –0.39 (1.02) –0.44 (1.09)
Range –3.69 to 4.09 –3.65 to 3.92
Missing 2 2
Heart rate > 100 b.p.m. 5 minutes after birth
Yes, n (%col, %row) 669 (92.5, 61.7) 415 (90.6, 38.3)
No, n (%col, %row) 54 (7.5, 55.7) 43 (9.4, 44.3)
Missing, n 1 4
continued
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
TABLE 17 Baseline data by colonisation status at 2 weeks’ postnatal age: infant characteristics (continued )
Characteristic
Colonisation with B. breve BBG-001
Yes (n= 724) No (n= 462)
Apgar score 5 minutes after birth
0–3, n (%col, %row) 20 (2.8, 55.6) 16 (3.6, 44.4)
4–6, n (%col, %row) 91 (12.8, 59.1) 63 (14.1, 40.9)
7–10, n (%col, %row) 598 (84.3, 61.8) 369 (82.4, 38.2)
Missing, n 15 14
CRIB II71
n 676 443
Mean (SD) 8.3 (3.4) 9.4 (3.5)
Range 1 to 20 2 to 19
Missing 48 19
b.p.m., beats per minute; CRIB, Clinical Risk Index for Babies; IQR, interquartile range.
a Despite complete data for gestational ages and birthweights there are four missing values for birthweight z-scores.
This is because four of the babies were below the reference range of age for any given weight of –0.326 to 23 weeks.
TABLE 18 Other early clinical data collected post randomisation by colonisation status at 2 weeks’ postnatal age
Characteristic
Colonised with B. breve BBG-001
(n= 724)
Not colonised with B. breve BBG-001
(n= 462)
Enteral feeding in the first 14 daysa
Number fed within 14 days of birth 723 455
Postnatal age at first feed (days)
Mean age (SD) 3.0 (1.6) 3.5 (2.3)
Median age (IQR) 3 (2–4) 3 (2–4)
Range (1–12) (1–14)
Type of milk received (0–14 days), n (%)
Any maternal breast milk 691 (95.4) 439 (95.0)
Any donor breast milk 157 (21.7) 99 (21.4)
Any formula 290 (40.1) 130 (28.1)
Maternal breast milk only (0–14 days), n (%)
Yes 307 (42.4) 238 (51.5)
No 417 (57.6) 224 (48.5)
Antacid and antibiotic use (0–14 days),b n (%)
Any antacid given 72 (9.9) 50 (10.8)
Antibiotics given in first 5 days 717 (99.0) 457 (98.9)
Antibiotics given between days 6 and 14 459 (63.4) 374 (80.1)
Total days of antibiotics days 0–14,
median (IQR)
8 (3–18) 14 (7–30)
IQR, interquartile range.
a Details of feeds were only collected for the first 14 days after birth.
b Details of medications only collected for the first 14 days after birth.
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Primary outcomes by colonisation
Despite the three primary outcomes all being less frequent in those babies who were colonised with
B. breve BBG-001 at 2 weeks, there was no clear evidence of benefit associated with colonisation.
The proportion of infants who had an episode of NEC Bell stage 2 or 3 was 6.5% in the colonised group,
compared with 12.6% in the non-colonised group (adjusted RR 0.68, 99% CI 0.43 to 1.09); the
corresponding figures for late-onset sepsis were 9.3% and 14.3% (adjusted RR 0.88, 99% CI 0.59 to 1.31)
and for death were 3.3% and 7.1% (adjusted RR 0.68, 99% CI 0.35 to 1.29) (Table 19).
Secondary outcomes by colonisation
Despite trends towards reduced rates of adverse outcomes in those babies who were colonised at
2 weeks, there was no clear evidence of the benefit for any of the secondary outcomes other than the
time to full feeds, which was lower in those infants who were colonised (Table 20 and Figure 9).
TABLE 19 Primary outcomes by colonisation status at 2 weeks’ postnatal age
Primary outcome
Colonisation with B. breve BBG-001
Yes (n= 724), n (%) No (n= 462), n (%) Adjusteda RR (99% CI)
Late-onset sepsisb 67 (9.3) 66 (14.3) 0.88 (0.59 to 1.31)
NECc 47 (6.5) 58 (12.6) 0.68 (0.43 to 1.09)
Death 24 (3.3) 33 (7.1) 0.68 (0.35 to 1.29)
a Adjusted for sex, gestational age at birth and randomisation within 24 hours of birth. Centre was excluded, as the
model did not converge. Allowances for correlations between multiple births are accounted for.
b Late-onset sepsis is defined as bloodstream infection with non-skin commensals after 72 hours’ postnatal age and before
46 weeks’ postmenstrual age.
c Necrotising enterocolitis Bell stage 2 or 3.
TABLE 20 Secondary outcomes by colonisation status at 2 weeks’ postnatal age
Secondary outcomes
Colonised with B. breve
BBG-001 (n= 724), n (%)
Not colonised with B. breve
BBG-001 (n= 462), n (%)
Adjusteda RR
(99% CI)
Late-onset sepsis,b NECc or death at
discharge home
106 (14.6) 114 (24.7) 0.79
(0.60 to 1.06)
Late-onset sepsis-related and microbiological outcomes
Positive blood culture for skin
commensal
134 (18.5) 130 (28.1) 0.78
(0.60 to 1.01)
Any blood culture taken after 72 hours 517 (71.4) 396 (85.7) Not convergedd
Number of blood cultures per infant
after 72 hours, median (IQR)
2 (0 to 4) 3 (1 to 6) 0 (0 to 0)
Bloodstream infection by organism
Enterobacteriaceae 23 (3.2) 23 (5.0) 0.88
(0.42 to 1.82)
Enterococcus 12 (1.7) 13 (2.8) 0.81
(0.29 to 2.22)
Staphylococcus 20 (2.8) 14 (3.0) 1.1
(0.45 to 2.64)
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TABLE 20 Secondary outcomes by colonisation status at 2 weeks’ postnatal age (continued )
Secondary outcomes
Colonised with B. breve
BBG-001 (n= 724), n (%)
Not colonised with B. breve
BBG-001 (n= 462), n (%)
Adjusteda RR
(99% CI)
Fungi 5 (0.7) 3 (0.7) 1.09
(0.17 to 7.13)
Other non-skin commensals 19 (2.6) 19 (4.1) 0.83
(0.36 to 1.88)
Antibiotic-resistant bloodstream infection
MRSA 0 2 (0.4) Too few data
VRE 0 1 (0.2) Too few data
ESBL-producing Gram-negative bacteria 2 (0.3) 4 (0.9) 0.30
(0.03 to 2.78)
Gentamicin resistant 1 (0.1) 0 Too few data
Isolates of organisms from other normally sterile sites
Suprapubic urine 0 1 (0.2) Too few data
Cerebrospinal fluid 5 (0.7) 6 (1.3) 0.67
(0.14 to 3.27)
Pleural cavity 0 0
Peritoneum 10 (1.4) 9 (2.0) 0.72
(0.22 to 2.33)
Other (joint fluid) 0 1 (0.2) Too few data
B. breve BBG-001 from any normally
sterile site
0 0 Too few data
Total days of antibiotics after 72 hours,
median (IQR)
8 (3 to 18) 14 (7 to 30) 5 (4 to 7)
Total days of antifungals after
72 hours, median (IQR) [range]
0 (0 to 0) [0 to 154] 0 (0 to 3) [0 to 58] 0 (0 to 0)
Feeding and growth
Reached full feeds, n (%) 718 (99.2) 447 (96.8)
Died before reaching full feeds 4 (0.6) 13 (2.8)
Postnatal age at first full feed (150ml of milk/kg/day), days
Median 13 17 1.36
(1.16 to 1.59)e
99% CI of median 12 to 14 15 to 18
IQR 9 to 19 11 to 26
Change in weight z-score (from baseline to 36 weeks’ postmenstrual age)
n 721 460
Mean (SD) –1.33 (0.92) –1.47 (0.91) 0.08
(–0.05 to 0.21)
Range –6.76 to 2.69 –6.02 to 1.23
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TABLE 20 Secondary outcomes by colonisation status at 2 weeks’ postnatal age (continued )
Secondary outcomes
Colonised with B. breve
BBG-001 (n= 724), n (%)
Not colonised with B. breve
BBG-001 (n= 462), n (%)
Adjusteda RR
(99% CI)
Other morbidities
Survivors to 36 weeks’ postmenstrual
age, n
699 428
Bronchopulmonary dysplasia (any O2 at
36 weeks’ postmenstrual age)
238 (34.1) 192 (44.9) 0.80
(0.67 to 0.95)
Severe bronchopulmonary dysplasia at
36 weeks’ postmenstrual agef
79 (11.3) 72 (16.8) 0.94
(0.66 to 1.34)
n 645 658
Hydrocephalus and/or intraparenchymal
cysts, n (n/N, %)g
38 (5.3) 40 (8.7) 0.71
(0.41 to 1.24)
n 691 441
Worst stage of retinopathy of
prematurity ≥ stage 3 in either eye,
n (n/N, %)
23 (3.3) 23 (5.2) 0.65
(0.31 to 1.37)
Length of stay
n 724 459
Total length of hospital stay (days),
median (IQR)
64 (46 to 91) 75 (53 to 104) 9 (4 to 14)
n 724 461
Intensive care stay (days), median (IQR) 8 (4 to 29) 18 (5 to 39) 4 (2 to 7)
High-dependency unit stay (days),
median (IQR)
16 (5 to 31) 23 (9 to 37) 4 (1 to 7)
IQR, interquartile range.
a RRs adjusted for sex, gestational age at birth and randomisation within 24 hours of birth. Centre was excluded as the
model did not converge. Allowances for correlations between multiple births are accounted for.
b Late-onset sepsis is defined as bloodstream infection with non-skin commensals after 72 hours postnatal age and before
46 weeks postmenstrual age.
c Necrotising enterocolitis Bell stage 2 or 3.
d Simple unadjusted model does not converge; Fisher’s Exact test has a p-value of < 0.0001.
e Hazard ratio.
f Severe bronchopulmonary dysplasia was defined as still receiving mechanical ventilatory support or, if breathing
spontaneously, still receiving more than 0.1 l/minute oxygen or 30% or higher supplementary oxygen.72
g An additional 21 babies (six in the colonised group and 15 in the non-colonised group) had reports of haemorrhagic
parenchymal infarcts but never progressed to have reports of hydrocephalus, porencephaly or periventricular
leucomalacia, of these one in the colonised and eight in the non-colonised group died before discharge from hospital.
N= number reporting, if N is not specified, the data are complete with no missing items.
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Safety
There were no reports of babies not tolerating the interventions. Although detailed data were not
collected, our understanding was that those parents who requested discontinuation of the intervention did
so because of intercurrent clinical problems, often suspected or proven NEC. We received no requests to
‘unblind’ the intervention.
There were no reports of positive culture of any bifidobacteria from any normally sterile site.
Analysed by intention to treat, there were no differences in the rates of stool colonisation by
antibiotic-resistant bacterial strains either at 2 weeks’ postnatal or 36 weeks’ postmenstrual age. At
2 weeks, 4.1% of stools from babies colonised with B. breve BBG-001 were positive for ESBL-producing
Gram-negative bacteria, compared with 1.7% of those not colonised with B. breve BBG-001 (Table 21);
this difference is not statistically significant. At 36 weeks’ postmenstrual age, the rate of ESBL-producing
Gram-negative bacterial colonisation was 3.8% in the colonised babies and 3.3% in the
non-colonised babies.
There were two reports of SAEs (Table 22): one baby allocated to the placebo group suffered fatal toxic
epidermal necrolysis and one baby allocated to the probiotic group survived a massive pulmonary
haemorrhage that was initially, apparently incorrectly, thought to be associated with a transfusion reaction.
Neither SAE was considered likely to be related to the interventions. There were no reports of SUSARs.
HR 1.36, 99% CI 1.16 to 1.59
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FIGURE 9 Kaplan–Meier plot of time to first feed by colonisation with B. breve BBG-001 at 2 weeks’ postnatal age.
HR, hazard ratio.
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TABLE 21 Secondary outcomes by colonisation status at 2 weeks’ postnatal age: stool microbiology
Secondary outcome
Colonised with B. breve
BBG-001 (n= 724), n (%)
Not colonised with B. breve
BBG-001 (n= 462), n (%)
Adjusteda
RR (99% CI)
2 weeks’ postnatal age
MRSA, n (%) 3 (0.4) 0 Too few data
VRE, n (%) 1 (0.1) 0 Too few data
ESBL-producing Gram-negative bacteria
n (%)
30 (4.1) 8 (1.7) 1.86
(0.72 to 4.80)
36 weeks’ postmenstrual ageb
MRSA, n (n/N, %) 1 (0.2) 0 Too few data
VRE, n (n/N, %) 1 (0.2) 3 (0.8) 0.21
(0.01 to 4.09)
ESBL-producing Gram-negative bacteria
n (n/N, %)
23 (3.8) 13 (3.3) 1.18
(0.49 to 2.82)
Missing 118 69
a Adjusted for sex, gestational age at birth, randomisation < 24 hours of age. Centre was excluded as the model did not
converge. Allowances for correlations between multiple births are accounted for (except for VRE, which is not adjusted
for gestational age).
b Fifteen babies died before 36 weeks’ postmenstrual age and 172 babies had no stool sample.
N= number reporting, if N is not specified, the data are complete with no missing items.
TABLE 22 Serious adverse events by intention to treat
Event
Trial group
Probiotic (n= 650) Placebo (n= 660)
Toxic epidermal necrolysis (fatal), n (%) 0 1 (0.2)
Pulmonary haemorrhage, n (%) 1 (0.2) 0
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Chapter 5 Discussion
This is the largest trial to date investigating the potential of a probiotic intervention to prevent NEC,late-onset sepsis and death in preterm babies. The probiotic tested was B. breve strain BBG-001. The
trial was undertaken and completed because, despite the publication of a number of randomised trials and
meta-analyses together with some strong recommendations for routine use of probiotics, there were
ongoing concerns about the quality of a number of the trials, lack of evidence as to what product might
be useful and, in particular, a lack of confidence that the babies included in the trials were representative
of the population in UK neonatal units.
The strengths of this trial are the use of a product with a single bacterial strain, which simplifies the
interpretation of results; the monitoring of colonisation, so that the extent of successful colonisation of the
active intervention group and cross-colonisation of the placebo group is known; and the size of the trial,
as it has adequate statistical power to give clear answers about the prevention of NEC and late-onset
sepsis. The aim was to recruit babies representative of the total English newborn infant population by
having minimal exclusions, and by recruiting and starting the intervention soon after birth.
This is the first trial of a probiotic in the newborn infant to be performed to ICH-GCP standards.
As with other published trials of probiotics, there was no evidence of short-term harm but, in contrast to
the sole other large published trial, the Australasian ProPrems trial,41 and the conclusions of the most
recent Cochrane review of this topic,35 this intervention in this population of babies showed no evidence of
benefit; in particular, there was no evidence of prevention of NEC.
This discussion will address the design and conduct of the trial, and the findings in the context of current
understanding of the pathogenesis of NEC and severe late-onset sepsis, and it will consider implications for
clinical practice and make recommendations for future research.
Trial design and conduct
Duration of trial
This trial relates to the prevention of major complications of preterm birth; the application for funding was
made in 2005 with a view to trial staff coming into post in during 2006 with recruitment over 30 months
from May 2007. In the event, staff came into post in September 2009, the set-up period was 3 months
longer than expected and it took 36 months to complete recruitment. That a trial of such importance for
the advancement of neonatal care should be so delayed is important for those planning and funding
large trials.
The initial delays were in large part related to regulatory issues around the interventions and were perhaps
inevitable. It became clear between the pilot and main trial that the intervention was to be classed as a
medicine; this was, we believe, the first application for a probiotic intervention to be granted clinical trial
authorisation and there was initially a lack of clarity about the standards that the product should meet.
The delays during the set-up phase and early recruitment related to the NHS research and development
(R&D) approval processes and, to a lesser extent, in some hospitals, the lack of staff with GCP training,
and are discussed in greater detail in this chapter. Once through these difficult early phases, the rate of
recruitment was as had been predicted (see Figure 3).
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Choice of product
A major criticism of published trials is the failure of the investigators to choose products based on
laboratory evidence and evidence from animal studies and preclinical studies in babies supporting their
possible efficacy. A problem has been the urgency felt by clinicians to identify interventions to prevent
late-onset sepsis and NEC and the lack of such scientific evidence forcing them to select interventions on
pragmatic grounds, testing simply what is available or, slightly preferable, a product used in a previous trial
that suggested possible efficacy.73 Our own choice of product was based on the evidence of nutritional
advantage in the trial of Kitajima et al.,43 the availability of a placebo, the potential to monitor stool
colonisation and the knowledge that the product had been used extensively in Japan and was regarded
as being safe. When it became clear that the intervention would be classified as a medicine and that a
clinical trial certificate would be necessary, we were fortunate that the product is manufactured to high
specification by the manufacturer and that data supporting its stability were available. This was particularly
important when it became apparent that there would be difficulty obtaining a second batch of product in
order to complete recruitment and an application had to be made to the MHRA to extend the use beyond
the original shelf life. The granting of the extension was contingent on our continuing to monitor the
viability of the product in each pack and to confirm the absence of contamination. The additional B. breve
BBG-001 viability data gained (see Figure 6) and the absence of any contaminants strengthens confidence
in the quality of this product.
Timing of start of intervention
There were a number of reasons why we were keen to begin the intervention early, the most important
being that we were keen to be as inclusive as possible and, anecdotally, were conscious that as the clinical
course of preterm babies becomes more complex in the days after birth, with events such as episodes of
milk intolerance and suspected sepsis, staff and parents may become more reluctant to recruit babies
into trials, resulting in the inadvertent exclusion of babies at greatest risk of complications. In addition,
whether or not babies are enterally fed in the days after birth, they begin to acquire flora from birth and
subsequently through handling and interventions such as passing feeding tubes. If one of the mechanisms
by which probiotics might protect against NEC and late-onset sepsis is by modifying the developing flora
and discouraging colonisation with potential pathogens, then it seems likely, although evidence is lacking,
that efficacy will be enhanced if given early. Some clinicians still withhold feeds from babies at highest risk
of NEC (i.e. those babies with growth restriction and evidence of intrauterine hypoxia); thus, delaying the
probiotic until some milk is tolerated will inevitably delay its administration. For example, the protocol for
the ProPrems trial74 involved early recruitment within 72 hours of birth but the intervention was not started
until at least 1ml of milk was being tolerated every 4 hours; consequently, the intervention was not
started until a median age of 5 days (interquartile range 4–7 days),41 whereas in the two published
trials39,42 the intervention was started irrespective of feeding at a median age of 2 days39 and 1 day.42
We were successful in that the median age at randomisation in the PiPS trial was 35 hours (see Table 7)
with the median age at the first dose of intervention being 44 hours; this was earlier than the median age
at first feed, which was 3 days.
Not being able to prepare the interventions in whole milk created a difficulty in that, although our
powders were completely indistinguishable, the probiotic powder was turbid when made up with water
and we had to resort to using dilute milk to prepare them. We are uncertain whether or not the additional
precaution of preparing the intervention in amber-coloured bottles was really necessary; none of our
investigators ever suggested that they could distinguish between the active intervention and placebo
preparations. Although it is not explicit in any of the published trials, several of which used no placebo
(see Table 1), it seems likely that in some the reason for giving the probiotic intervention in milk was to
achieve masking.
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In our case the choice of the elemental formula in which to suspend the intervention, Neocate, was made
after discussions with gastroenterology and dietitian colleagues. To have used breast milk, which would
have been our first choice, was impracticable because of variable availability and opacity. It seemed
inconceivable that 1ml of one-eighth-strength Neocate could impose such a metabolic or immunological
stress on the intestinal epithelium that it could cause a clinical problem. We were concerned, however,
that the use of any formula might discourage some parents from agreeing to their baby entering the trial.
Detailed data were not collected but we regularly questioned our investigator colleagues on whether or
not this was a problem. After reassurance that it was believed to be safe and that it would not interfere
with successful establishment of breastfeeding, there seemed to be very few instances in which it was a
factor in parents refusing to enrol their baby.
Dosage
The trial published by Kitajima et al. in 199743 is the only other study to have used this product. In that
study, the intervention was prepared in 2ml of water and given in ‘two or three’ divided doses. We were
not keen either to impose this workload on staff or to retain the product for long periods of time once
made up. We increased the volume used to suspend the powder from 2ml to 3ml to make it easier for
staff administering the products to avoid disturbing the maize starch residue when drawing up the
1-ml dose. We estimated that the minimum bacterial count we were likely to find even with a more dilute
suspension would be around 6.7 × 107 CFUs, which remains within the range used in previously
published trials.
This is the first trial to have monitored the numbers of bacteria that were being given to babies throughout
recruitment. This was particularly important since the product was administered beyond the shelf life that
had been specified by the manufacturer. We had undertaken to stop recruitment should the number of
viable bacteria fall below the threshold recommended by the manufacturer of 2.2 × 108 CFUs (8.3 log10-CFUs)
per sachet, despite the fact that the evidence for that number is not clear. The data we received from the
laboratory during recruitment all suggested that the bacterial counts were declining at a predictable rate
and remaining well above the threshold. The active intervention given to the final recruits was inevitably
analysed after the end of the trial and the count in a single pack had fallen to the threshold. There is,
however, no evidence that rates of successful colonisation reduced during the trial, and we have no
evidence to suggest that the dose was inadequate.
The intervention was stopped at 36 weeks’ postmenstrual age rather than continuing it to discharge,
as has been done in some trials, as it was felt that parents would prefer it not to be stopped when
the baby went home. When babies went home earlier than 36 weeks staff were encouraged, if there
was opportunity, to discontinue the intervention a few days before discharge.
Whether or not it is necessary to continue the intervention this long in order to achieve prolonged
colonisation has not been systematically studied and is likely to be dependent on the gestational age of
the baby, use of antibiotics and feeding. In one small study,75 it was noted that L. paracasei NFBC 338
could still be detected in the stool 2 weeks after a single dose given on day 4 to low-birthweight babies
who received no antibiotic subsequent to the probiotic. In the PiPS trial, stools were obtained at just two
time points, 2 weeks’ postnatal and 36 weeks’ postmenstrual age, so we have no information about
coming and going of colonisation in between the two time points; however, as 9.5% of the 571 babies in
the probiotic group who were successfully colonised at 2 weeks were no longer colonised at 36 weeks’
postmenstrual age, we would suggest that in current clinical practice it is probably necessary to continue
the intervention at least until the baby is beyond the peak time of risk of NEC, around 32 weeks’
postmenstrual age.
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None of the previously published trials gives detailed data about exactly how many doses of the
intervention babies received, implying, in the majority, that the intervention was given continuously over
the prescribed period. Given the anxiety often experienced by nursing staff about giving milk to babies
with feed intolerance or any suggestion of early NEC or sepsis, this seems very unlikely. We left the
decision of whether or not doses should be omitted to the local clinicians and suggested definite
withholding only in the circumstance of suspected intestinal perforation, although we imagined that if a
dose of the probiotic was inadvertently given in that situation it could not do any harm. We did give
strong encouragement that after resolution of episodes of NEC, if the intervention had been discontinued,
it be recommenced, and we are aware that this was done on multiple occasions. We received no
reports whatsoever of problems tolerating the interventions and were pleased that the proportion of
recommended doses given was high at 85%.
The use of necrotising enterocolitis and late-onset sepsis as trial end points
We had concerns about the objectivity of both NEC and late-onset sepsis as outcomes in clinical trials.
The diagnosis of NEC is made on clinical and radiological features (intestinal intramural gas and/or
perforation) supported by haematological markers and, in those who die or come to surgery, on the
macroscopic and histological appearance of the bowel. The applicability of Bell staging, which for many
years has been the method most frequently used to categorise cases, to the contemporary population of
very preterm babies with NEC has been challenged,76 but the method has not been replaced by anything
more reliable. The radiological sign of intramural gas can be very difficult to detect, with clinicians
disagreeing about its presence; the final diagnosis in non-fatal, non-surgical cases is to a great extent
dependent on the total picture and the experience of the clinicians and it was agreed that, for trial
purposes, whether or not a baby had the disease and the staging thereof should primarily rest with the
attending clinical staff. In practice, this is complicated by the way in which the clinical service is organised
with only a small number of neonatal units providing neonatal surgery, which results in babies with
suspected or proven NEC frequently moving between hospitals while the clinical picture is evolving.
It was for these reasons that we felt that it was essential to review all cases with any abdominal pathology
after data collection had ended. This process generated new queries to PIs, particularly when the final
diagnosis provided did not fit the detailed data, for example stage 2 NEC with no diagnostic radiological
features, and it resulted in changes to the final diagnosis in 10 cases. As a result we are as confident as we
feel it is possible to be about the accuracy of the NEC diagnosis, but without this rather labour-intensive
process we believe that a number of cases would have been wrongly categorised.
Many of the published trials studying the effect of probiotic interventions on sepsis include in their
definition ‘any’ positive blood culture. One of the great difficulties in studying rates of neonatal sepsis has
been reliably distinguishing between positive cultures of S. epidermidis that represent true infections and
those that arise from contamination from the skin during blood sampling. It is possible that the great
range of reported infection rates and the lack of consistency of effect on sepsis is in part attributable
to inclusion of non-infected cases with positive blood cultures. The Australasian ProPrems trial,41 for
which sepsis was the primary outcome, addressed this problem by using strict criteria to define infection
with S. epidermidis involving duplicate positive cultures and duration of antibiotic use. The rationale
underpinning the pragmatic approach taken for the PiPS trial, which for the primary outcome excluded all
positive cultures of S. epidermidis, is described in appendix 1 of the protocol.
As planned, our microbiological outcome data were collected directly from hospital routine laboratories.
Although we still believe that we would have had difficulty collecting reliable data about the antibiotic
sensitivities of cultured bacteria from neonatal clinicians, this methodology was very laborious and,
although we received a high level of support and co-operation from many hospital microbiologists, the
process in some hospitals was complicated because of the subcontracting of pathology services. Although,
on another occasion, we would follow the same procedure, we would also ask clinicians, in parallel, to
report positive blood cultures, since these are unusual and important events and data are likely to be
accurate. Such reports would augment and aid interpretation of the often rather complex data received
from laboratories that received numerous samples, often seemingly with inadequate information from
clinical staff as to their source and the indication for their collection.
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The trial population
The gestational age range of eligible recruits (23+0 to 30+6 weeks’ gestation) was selected in order to
capture the babies at highest risk of NEC and late-onset sepsis. The importance of gestational age as a
risk factor is apparent within the trial data, with all three primary outcomes falling sharply with increasing
gestation age within this target range (see Figure 7), but the greater number of births at higher gestational
age means that the need for effective prevention remains high. Cochrane reviews of the role of probiotics
to prevent NEC prior to that published in 201430,32 argued that the evidence of efficacy in preterm babies
with a birthweight > 1 kg supported routine use. More recently, with publication of the ProPrems trial,41
that recommendation has been extended to include the extremely low-birthweight group with birthweight
< 1 kg. In a recent review of the published literature, Abrahamsson et al.73 are generally critical of the
quality of published trials but nonetheless recommend that the most important need is for future trials to
address the extremely low-birthweight group. The ProPrems trial41 did indeed find evidence of decreased
NEC in a population of babies born before 32 weeks’ gestational age, but the rate of NEC in the placebo
group was low, at 4.4%, and the upper 95% CI of the number needed to treat to prevent a single
case of NEC was 333. There did appear to be a greater effect in the subgroup with a birthweight > 1 kg
(0.3% probiotic vs. 3.2% placebo, compared with 4.3% probiotic vs. 5.9% placebo in the extremely
low-birthweight group), but the numbers are small and the interaction p-value was 0.08. We would still
argue that the case for routine use in the UK for babies of birthweight > 1 kg is not made and that the
population included in the PiPS trial is the one we need to study.
Participating hospitals
The recruiting hospitals in the PiPS trial were all in or close to London, UK. The clinical service is organised
into networks, with the care of the majority of babies born before 27 weeks’ gestation being in the larger
tertiary centres. The recruiting hospitals included both tertiary and secondary centres in order to ensure a
spread of gestational ages within the population. During the course of the trial some hospitals further
afield expressed enthusiasm to join, but by that time the organisation of the trial was established and we
did not have the capacity to increase the number of recruiting centres. The initial decision to confine the
trial to the south-east of England was made for two reasons. The first was that in the early planning stages
it was expected that the recruitment period for the PiPS trial would overlap with the randomised trial of
oxygen targeting, the Benefits of Oxygen Saturation Targeting, Clinical Trial (BOOST),77 which involved
many major neonatal centres but none in London. In the event, the beginning of recruitment to PiPS was
delayed and hospitals close to London that had recruited to BOOST joined. The second was that
considerable personal support by the team of trial research nurses would clearly be needed to both
recruiting and ‘step-down’ centres in making up the interventions. This would have been more difficult
and expensive had they been further afield. The alternative would have been to fund research nurses in
participating centres but, with an intervention that continued until 36 weeks’ postmenstrual age and a
pattern of clinical care that involves babies moving between intensive and lower-dependency units, it was
concluded that that was impractical.
Setting the trial up and early recruitment problems
We had planned for a 6-month period from the beginning of the trial until the start of recruitment but
required 9 months. The principal reasons for this were delays in gaining NHS R&D approvals and, in a
number of hospitals, the lack of anyone on the staff who had received GCP training and could act as PI
or take informed consent. Our original plan, because we knew that the babies would move between
hospitals during the course of the intervention, was not to begin recruitment at any hospital in a network
until all hospitals in that network had the necessary approvals in place. This would unquestionably have
been an advantage, but such were the delays at some centres that it was not practicable. When a baby
was recruited we asked which hospitals he/she might be transferred to in the hope that we could expedite
the gaining of approvals in those places. This, however, was only partially successful, and in the early
stages of recruitment a number of babies had to discontinue the intervention prematurely because they
were transferred to a non-approved site.
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Particularly in smaller hospitals, staff found it difficult to get time off to attend GCP courses when the
online course was unavailable. As a consequence, few of the smaller hospitals had more than one person,
or possibly two people, who could take consent. This problem was compounded by local NHS trust rules
preventing nurses, however experienced and familiar with the trial they were, from taking consent in a trial
involving a medicinal intervention.
These problems resulted not only in delay in opening sites (see Table 3) but also in very slow early
recruitment (see Figure 3), so that after 6 months it had to be questioned whether or not the trial could be
delivered. The possibility of engaging more recruiting sites was rejected and with a programme of constant
hands-on encouragement and training from trial staff, coupled with support from the Medicines for
Children Network staff based at Great Ormond Street Hospital in identifying research nurses, recruitment
accelerated so that the total duration was only 6 months longer than originally planned.
The development of standardised procedures for the governance of research in the NHS over the past
20 years has greatly increased the quality and accountability of much clinical research but the resultant
bureaucracy can at times be obstructive and still needs to be honed further. The extreme that we
encountered was the situation of a hospital in which the staff were keen to collaborate and act as a
continuing care site but who were prevented from doing so by their trust, which, because of the financial
implications, would agree only if it could be a recruiting centre. Any baby recruited into the trial who was
transferred to that hospital for step-down care had to discontinue the intervention despite the parents
having agreed for their baby to receive the intervention until 36 weeks’ postmenstrual age and the
willingness of the staff to administer it.
Less dramatic, but more frequent, and equally disruptive to the conduct of the trial, were examples of babies
who were transferred to hospitals that could not have been predicted and the trial staff encountering such
extremes of obstructive behaviour and seeming lack of insight into the importance of protocol adherence on
the part of local R&D staff, who argued that their sole interest was to protect the patients, that approval
could not be gained in time for the intervention to be continued smoothly. It was sometimes possible to
accelerate things by the chief investigator ringing personally, on occasion to the hospital’s director of R&D,
but this really should not be necessary and was not always possible or even effective.
Results
Identification of Bifidobacterium breve BBG-001
This is the first multicentre trial of a probiotic intervention in the newborn infant systematically to have
studied the presence of the administered probiotic strain in stools as a marker of intestinal colonisation.
It was beyond the scope of this trial to collect stools more frequently and so the data serve to provide
a snapshot at the two selected time points. The 2-week time point was selected as the basis for the
secondary analysis of primary outcomes by ‘colonisation’ because it was thought that in the majority of
cases it would be before the onset of NEC and it was speculated that if the intervention was to provide
protection it would perhaps have needed to colonise the intestine by around this time. We have no data
for the presence of B. breve in the stools between these two time points, but it is clearly possible that,
even within the group given the probiotic, colonisation may come and go as, of those babies with samples
at both time points, 54 (63%) of the 86 babies who were not colonised at 36 weeks’ postmenstrual age
had been colonised at 2 weeks. The selective medium used for culture was provided by the manufacturer
and said to be strain specific; it was validated at species level by MALDI-TOF. It was decided early in the
trial, if there was sufficient stool, to augment culture with PCR because of concerns that it was sometimes
taking several days for samples to reach the laboratory. The PCR is based on a method reported by the
manufacturer and again is described by the manufacturer as specific for the intervention strain. PCR, in the
context of this trial, has the advantage not only that it might detect bacteria that have died during any
delay in reaching the laboratory but also that it might detect bacteria whose growth is inhibited in culture
by antibiotic given to the baby.
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The proportion not colonised by culture but found to be colonised by PCR was 38% in the B. breve group
and 18% in the placebo group. We have not separately evaluated the PCR in comparison with culture and
cannot exclude the possibility that the PCR might have identified some strains inaccurately and be giving
a high false-positive rate. In selecting strains of commensal bacteria to develop for commercial use,
manufacturers will inevitably choose those that colonise readily. It seems unlikely that the high rates of
cross-colonisation we found are confined to B. breve BBG-001 but, in the absence of such detailed
colonisation data using any other probiotic products, we cannot comment further.
Successful colonisation by Bifidobacterium breve BBG-001 of babies in the
probiotic arm of the trial
Despite the early administration of the probiotic intervention, using both culture and PCR we detected
B. breve BBG-001 in the stools of only 85% of babies in the probiotic arm of the trial at 2 weeks’
postnatal age. We did not have the resource to do PCR at 36 weeks’ postmenstrual age; the number of
those positive by culture alone had risen from 74% at 2 weeks to 84%.
The technique of PCR appears to be very sensitive and, although we were surprised not to detect higher
colonisation at 2 weeks, there are multiple reasons why colonisation may not be complete. Antibiotic use
in these babies, at least in the first few days after birth, was almost universal. Furthermore, over 10%
received an antacid in the first 2 weeks. We were surprised that this number was so high, and it is likely
that this had an impact on the acquisition of bacterial flora but the detail has not been researched. It was
encouraging that over 90% of infants received some maternal breast milk, as the bifidogenic properties
of breast milk are well recognised; however, the actual volumes received by many babies were likely
to have been small. It is interesting that in the univariable analysis of determinants of colonisation
(see Table 15) babies were disadvantaged by starting feeds later and seemed to be particularly
advantaged, in this respect, if receiving a combination of breast and formula milk. One can speculate that
this might be attributable to faster advancement of volumes of feeds or, possibly, to the bifidogenic
properties of the breast milk being augmented by the addition of oligosaccharides to preterm formula.
None of these feeding effects remained significantly associated with colonisation in the multivariable
models, for which the overwhelming effects were the negative impact of prolonged antibiotic use and the
advantage of higher gestational age.
The determinants of interactions between probiotic bacteria and the human infant gut are comparatively
poorly understood.78 For example, at the present time the extent to which newborn infants at different
gestational ages express the specific epitopes required for binding of probiotics is not known. Adhesion to
cell surface-associated structures has been shown to be an important determinant of metabolic and
immune interactions for both commensal and pathogenic bacteria in animal models of colonisation and
disease.79,80 Motherway et al.81 described type IVb tight adherence pilus expression and associated genetic
determinants in B. breve UCC2003 using a mouse model of colonisation. The epitopes for pilus adhesion
in this mouse model have yet to be identified. Specific human mucus binding pili have been described in
the probiotic strain L. rhamnosus GG.82 It is known that skin structures are poorly developed in infants
born before 34 weeks’ gestation, that the skin develops rapidly in the few weeks after birth but that in the
most preterm infants a fully functional stratum corneum may not have developed by 4 weeks’ postnatal
age.83 It may be that the lack of benefit associated with enteral supplementation with B. breve strain
BBG-001 in this study reflects the immaturity of the gastrointestinal tract of the preterm infant in the early
weeks of life. Further research may help to elucidate the importance of adhesion and other types of
probiotic interaction in determining preterm infant outcomes.
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Colonisation by Bifidobacterium breve BBG-001 of the placebo arm of
the trial
In order to minimise the possibility of cross-contamination, local nursing staff received training from the
trial staff emphasising the importance of completing preparation of the intervention for each baby,
then cleaning all working surfaces before progressing to the next. In addition, staff were reminded of
the importance of maintaining strictly routine infection control procedures in clinical areas. Despite these
precautions, B. breve BBG-001 was detected by culture in 49% of infants in the placebo group by
36 weeks’ postmenstrual age (Table 13).
Pooled (probiotic- plus placebo-allocated babies) colonisation data by site were monitored by the trial
management team throughout recruitment. We were conscious that cross-colonisation was taking place,
as from a number of sites around 70% of stool samples were colonised. We were looking out for any sites
in which there was a clear excess of colonised babies, but because of the movement of babies between
sites and interpretation of small numbers it was never possible to be confident that any individual unit was
a ‘high outlier’. Rather than target additional training at specific hospitals, we informed investigators that
it was clear from the data that cross-colonisation was occurring and we reminded them of the importance
of taking precautions.
The rates we found of colonisation of babies allocated to receive placebo were similar to those reported in
the study of Kitajima et al.43 using the same product (44% at 6 weeks after birth) and in our own pilot
study (35% at 4 weeks after birth).
Colonisation data have recently been reported for a subset of babies (five in the probiotic group, seven in
the placebo group and 31 non-enrolled babies) from a single site involved in the ProPrems trial.41,84
The intervention included three bacterial strains, S. thermophilus TH-4, B. infantis BB-02 and B. lactis BB-12;
stools were analysed by PCR and the presence of at least two of three strains was classified as cross-colonisation.
All of the babies allocated to receive probiotic, one of those allocated to receive placebo and two of the other
babies were colonised at postnatal ages ranging from 35 to 174 days. At first sight this rate of cross-colonisation
seems low compared with our own, but the numbers are too small to be confident about this and it is not
clear why the definition of colonisation involved two rather than one bacterial species.
It is most unlikely that cross-colonisation is unique to the PiPS trial.
The combined effects of incomplete colonisation of the active probiotic with only partial colonisation of the
placebo group might lead to underestimation of any potential benefit. The intention-to-treat analysis
undertaken for subgroups categorised by colonisation status does not suggest, however, that efficacy in this
trial is impacted by cross-colonisation (see Figure 7). Nor, in the analysis of primary outcomes by colonisation
at 2 weeks (see Table 19), is there clear evidence of advantage associated with B. breve BBG-001 colonisation.
Probiotics in Preterm infantS trial results: outcomes
We found no evidence of benefit for this probiotic intervention in this population of preterm babies for
any of the three primary outcomes or for any of the secondary outcomes, which included measures of
the severity and time of onset of NEC, other measures of late-onset sepsis and a range of important
neonatal morbidities.
The failure to show a reduction in NEC or mortality is at variance with a number of meta-analyses,27,30–32,35,63
including the most recent Cochrane review, and with the recently published large multicentre ProPrems trial41
that recruited in Australia and New Zealand and which, while failing to find evidence of benefit for either
sepsis or mortality, did show a protective effect for NEC (2.0% active intervention group vs. 4.4% placebo
group). Interestingly, the time of onset of NEC Bell stage ≥ 2 at a postmenstrual age of 30 weeks is earlier in
the PiPS trial than in the data based on a Canadian population, but is similar to preliminary data for time of
onset of serious (surgical and/or fatal) NEC at a median postmenstrual age of 30 weeks (interquartile range
28–32 weeks’ postmenstrual age) in a 2-year prospective cohort of 14,294 babies born between 23 and 31
completed weeks of gestation admitted to neonatal units in England in 2012 and 2013.85
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Exposure to maternal corticosteroid and early maternal breast milk, both protective against NEC, was high
in both the PiPS and the ProPrems trials, but the rates of NEC and pathogen-related sepsis are higher in in
the placebo group in this trial (NEC 10.0% vs. 4.4% and pathogen-related sepsis 11.7% vs. 8.7%). The
baseline data suggest that a higher proportion of the babies in the PiPS trial are small for their gestational
age, which might account for some of this difference. Variations in rates of major morbidities in preterm
populations are, however, well recognised and often difficult to explain, most likely being related to
variation in baseline risk factors and characteristics of the clinical service. One comment that has been
made in a number of commentaries on the possible routine use of probiotics is that probiotics might have
greater effect in populations with ‘higher’ rates of NEC, but this is not supported by our findings.
We undertook subgroup analyses (see Figure 7), as described in the trial statistical analysis plan
(see Appendix 12), together with an additional analysis to aid comparison with the ProPrems data,41 with
the participants categorised by gestational age < 28 weeks versus ≥ 28 weeks. These subgroup analyses
are important because in the most recent Cochrane review35 the previous recommendation,32 which stated
that probiotics should be routinely used in those with a birthweight > 1 kg but that more evidence of
efficacy was needed at lower birthweight, was revised and extended to suggest that routine use be
considered at all birthweights. The ProPrems trial subgroup analyses by birthweight and gestational age
suggested evidence of efficacy to reduce both NEC and sepsis in those of birthweight > 1 kg and
28 weeks’ gestation, but not in the smaller, less mature, babies. In contrast to the results of the ProPrems
trial, we found no evidence of trends towards a decrease of NEC associated with B. breve BBG-001 with
increasing gestation or birthweight. Inspection of the data suggests a trend towards lower rates of sepsis
in those allocated to receive probiotic, but this does not reach statistical significance. The subgroup
analyses do show two statistically significant effects: decreased rates of sepsis in the probiotic group
(2.8%) compared with the placebo group (7.3%) (adjusted RR 0.39, 95% CI 0.16 to 0.96) for those born
at 28 or 29 weeks of gestation and increased mortality in the probiotic group (12 cases, 3.6%) compared
with the placebo group (three cases, 0.9%) (adjusted RR 3.93, 95% CI 1.14 to 13.56). However, a large
number of tests have been performed, and the numbers are small, and these results should be treated
with caution. The interaction tests for the subgroup analyses are all statistically underpowered. A possible
confounder in the PiPS trial is the high rate of colonisation by B. breve BBG-001 of the placebo group. The
intention-to-treat subgroup analysis of the primary outcomes by colonisation status at 2 weeks (see Figure 7)
does not suggest, however, that efficacy is impacted by cross-colonisation. This conclusion is supported by
the secondary analysis of the primary outcomes in those babies from whom a stool sample was received at
2 weeks, not by intention-to-treat but by colonisation status (see Table 19), which, while showing trends
towards lower rates of sepsis, NEC and death in those colonised, fails to reach a significant difference for
any outcome. The same is true for the analyses of secondary outcomes by colonisation status at 2 weeks,
except for statistically significant results showing earlier achievement of full feeds and suggesting reduction
of bronchopulmonary dysplasia associated with successful colonisation (see Table 20).
The conclusion of the logistic regression analysis performed to study determinants of successful
colonisation in those infants who were given B. breve BBG-001, that increasing gestation is the most
important determinant of successful colonisation and use of antibiotics beyond the fifth day after birth the
most important association of failure to colonise, may be interpreted to suggest that in this trial population
successful colonisation is perhaps simply a marker of babies at lower clinical risk of adverse outcomes and
that this explains the trends towards fewer complications when analysing by colonisation.
Much of the reason for the strong recommendations of some authors for routine probiotic use is the
finding of the meta-analyses of significant reduction in all-cause mortality.35 Together, the ProPrems41 and
PiPS trials have recruited over 2400 babies, which is over one-third of all babies recruited into over
20 probiotic trials. That neither ProPrems nor PiPS found any evidence of benefit to reduce mortality in
intention-to-treat analyses has to raise serious concerns about the findings of the meta-analyses and
consequent recommendations.
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The secondary analysis of outcomes by colonisation at 2 weeks was planned because we expected that,
because of the previous report of Kitajima et al.43 and our own pilot study, we would find considerable
cross-colonisation of the placebo group and that any therapeutic impact of the intervention would be
clear only by studying outcomes in the population successfully colonised irrespective of their treatment
allocation. That we found trends towards lower rates of the primary outcome and a range of secondary
outcomes but that they still failed to reach statistical significance confirms the lack of evidence of efficacy
of this particular probiotic intervention to reduce complications of prematurity in this population.
Safety
As in all other trials of probiotic interventions in the newborn infant, we received no reports of problems
administering the intervention and no reports of positive cultures of any bifidobacteria.
We encouraged clinicians to ensure that hospital microbiologists knew that this intervention was being
given, but are aware from our contacts with microbiologists to collect culture results that the message
was not always relayed around departments. The few reports there have been of bifidobacteria sepsis
suggest that the infection is usually very mild and easily treated. It is not clear that anaerobic cultures are
performed on all specimens or, if it is grown, if laboratory staff are unaware that a baby is receiving
bifidobacteria they might be dismissed as contaminants on a routine culture. It is possible that in this and
in other trials bifidobacteraemia is missed and under-reported. Nonetheless, even if this is the case,
short-term safety appears to be good.
There is interest in the possibility that probiotics might be useful to reduce carriage of antibiotic-resistant
pathogens,86 but, conversely, theoretically, by increasing microbial diversity, they might increase pathogen
carriage. Our results were reassuring in this respect. Although, overall, around 6% of babies from whom
we received stools were colonised at one or other time point with MRSA, VRE or ESBL, there was no
evidence of difference between the groups whether categorised by allocation or colonisation.
Longer-term safety data for probiotic interventions in preterm babies are almost completely lacking.
There is a reassuring report of growth and development87 of babies followed up to the age of 3 years from
one of the earlier trials conducted in Taiwan20 but no trial has been designed with adequate power to look
at important long-term health outcomes including atopic disease. The ProPrems trial41 has a follow-up
component that promises to begin to fill this void, but those results are not yet available.
Generalisability of the results
A major objective when designing the PiPS trial was to ensure the representativeness of the trial
population. Records of all potentially eligible babies, the precise numbers of parents who were approached
and reasons for refusal for their baby to join the trial were not required by the trial protocol. The view of
the investigators was that such data are often inaccurate and we were conscious that, for this trial, the
overwhelming reason for eligible babies not being recruited would be the lack of a staff member available
who was familiar with the trial and who also had GCP training. We aimed to ensure that those who
were approached were representative of the total preterm population by minimising exclusions and both
recruiting for and beginning the intervention early, making it more difficult to exclude babies for spurious
clinical reasons, which, purely anecdotally, we suspect often happens.
The PiPS trial population is strikingly multiracial, with the mothers of 56% of the babies being white,
20% being Afro-Caribbean and 12% with origins in the Indian subcontinent. Race is not recognised as a
risk factor for the outcomes of this trial, but the racial mix might be related to the observation that the
average birthweight was slightly low for gestational age and it is well recognised that intrauterine growth
restriction is a risk factor for both NEC and late-onset sepsis. The gestational age-based mortality of the
babies in the trial (see Figure 7) is very similar to that reported nationally for neonatal unit admissions in
2009 in England88 (data from 110 neonatal units with details to discharge or death for 34,635 babies
born before 33 weeks’ gestational age): 60% mortality rate at 23 weeks’ gestational age, 38% at
24 weeks’ gestational age, 27% at 25 weeks’ gestational age, 16% at 26 weeks’ gestational age,
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11% at 27 weeks’ gestational age, 6% at 28 weeks’ gestational age, 4% at 29 weeks’ gestational age and
2% at 30 weeks’ gestational age. NEC lacks a standard agreed case definition and the incidence is not
available from UK routine national data; the recording of episodes of infection is incomplete on the national
database. The rates that we found in the trial for NEC and late-onset sepsis in the placebo group (10.0%
and 11.7%, respectively) were within the ranges that we had specified in the power calculation that were
based on routine data collected for neonatal admissions in and around London in the years preceding the
trial and similar to rates quoted in large observational studies.59,60 On balance, we believe that the trial
population is certainly representative of the population in south-east England and we are not aware of any
good reasons why these results should not be extended to neonatal populations in the rest of the country.
Why does the probiotic intervention in the Probiotics in Preterm infantS trial
show no evidence of benefit? Probiotics in Preterm infantS in the context of
other trials in preterm babies
In the context of the variable effects on sepsis and lack of effect in multiple meta-analyses we attempted
to clarify the role of B. breve BBG-001 to reduce late-onset sepsis by, for our primary outcome, considering
only septicaemias caused by definite pathogens. That we found no benefit is disappointing but not
unexpected. It was perhaps more surprising that the ProPrems trial41 showed no evidence of improved
mortality associated with the three-strain probiotic intervention. In the context of that trial, which we
would argue is the first large well-designed preterm probiotic trial to be published, it is possibly less
surprising that we similarly found no evidence of reduced mortality associated with B. breve BBG-001
administration in the PiPS trial. However, despite our criticisms and those of others of the quality of many
of the published trials,34,73 we were surprised that we have been able to find no evidence of benefit to
reduce NEC in a clinical environment with an incidence of definite NEC (Bell stage ≥ 2) of around 10%.
At first sight it might be thought that we have missed an effect because of loss of statistical power
through incomplete colonisation of the active intervention group and cross-colonisation of the placebo
group, but our intention-to-treat subgroup analyses by colonisation and analyses of outcomes by
colonisation do not support this view. Furthermore, we were forewarned of this as a potential problem
and went to great lengths to provide training to minimise the effect; it seems most unlikely that either
cross-infection rates in the hospitals involved in the PiPS trial are very different from elsewhere or that this
has not also been a characteristic of other trials of probiotics.
The results of the PiPS trial might be negative in the sense of identifying a preventative therapy but they
are most important in the story of probiotic trials and the search for a means to prevent NEC and
late-onset sepsis.
There are many reasons why this intervention might have failed.
In the context of the wide range of products used in previously published trials34,63,73 it is too simplistic to
simply dismiss this result as being because we chose the wrong product. The evidence we have, as
discussed earlier, from laboratory, animal and limited human data all suggests that different bacterial
strains have different protective roles at the intestinal mucosal surface; this is biologically plausible and
explains why we are dependent on such an enormous range of commensals for good health. The
increased availability of molecular techniques to study the microbiome has led, over the period since the
PiPS trial was designed in 2004–6, to an explosion in knowledge of the microbiome, not only in health
but in a range of disease states including NEC and late-onset sepsis in the preterm baby.15–17,89,90 That
explosion of knowledge is not confined to the bacteria that inhabit the intestine but also includes other
compartments of the body, most notably for the neonatologist, maternal breast milk91 and the complexity
of interactions between the microbiome and the immature intestinal immune system that underpin the
pathophysiology of NEC.4,92,93 Although we remain convinced that the key to unlocking the challenge of
preventing these neonatal catastrophes lies in this area of biology, it seems naive from the current vantage
point to think that this might be achieved by giving a product with a single or even two or three
bacterial strains.
DOI: 10.3310/hta20660 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 66
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Costeloe et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
Combining trials of different probiotics in meta-analyses
The very strong and often emotional pressure that has been put on clinicians by a number of authors to
provide probiotics routinely for preterm babies has been based on no single well-designed large trial but
on a series of meta-analyses, the most recent of which was the Cochrane review35 published in 2014,
which included 23 trials and over 5500 babies. Other authors have repeatedly challenged not only the
rigour of a number of the trials but also the validity of combining trials using such disparate interventions
in meta-analyses. We would argue that the results of the PiPS trial further strengthen the argument that
combining trials using different probiotic interventions in meta-analyses should be resisted.
Conclusions
Implications for health care
Necrotising enterocolitis and late-onset sepsis remain among the most important causes of death and
life-long morbidity in surviving preterm babies. Rates of preterm birth in the UK are among the highest in
the developed world94 and are rising;95 therefore, preterm birth represents a major public health issue and
the challenge to find interventions to prevent NEC and late-onset sepsis is urgent. We are aware that
there is currently a rise in the use of probiotics on UK neonatal units given to prevent NEC. The data from
this trial do not support this practice. The short-term safety profile for probiotic interventions for the
individual baby is highly favourable, but there are almost no published outcome data beyond the initial
hospitalisation, and the use of probiotics on a neonatal unit will impact not only on the developing
microbiome of the babies for whom they are prescribed but also, through cross-colonisation, on that of
other babies within that unit.
A number of commentaries have suggested that it is perhaps unethical not to inform parents about the
evidence of probiotics to prevent NEC29 and that, when given the evidence, parents would be likely to
elect that their baby should be given them.96 This, however, obviously depends on the interpretation of
the data by the responsible clinician, the manner in which he or she presents it to the parents and the
availability of a product with adequate quality control. The data from this trial provide no evidence that
routine supplementation with B. breve BBG-001 would affect the risk of late-onset sepsis, NEC or death in
this population.
Recommendations for research
Regulatory considerations and neonatal trials
Although there has been progress in standardising and centralising procedures to ease the conduct of
trials, it remains necessary to gain local hospital approvals for those involving inpatients. This is a particular
problem for trials recruiting preterm babies, whose clinical care is organised in such a way that they
inevitably move between hospitals, sometimes along unpredictable pathways, and it was a major threat to
the success of this trial.
This problem may be eased if GCP training was provided for all medical neonatal trainees and consultants,
and for interested nurses, who could additionally be able to act as the PI for trials of IMPs, although some
hospitals have local rules preventing this. Furthermore, if a baby is transferred after any intervention is
complete and the only requirement is to collect outcome data, the procedures for approved members of
the trial team to access case notes could be further simplified.
Standardisation of definitions of outcomes
The diagnosis of both NEC and late-onset sepsis has an element of subjectivity, and neither has an
internationally agreed case definition either for epidemiological or for drug regulatory purposes.
This complicates the interpretation of individual published neonatal trials and undermines the validity of
combining the trials in meta-analyses. The PiPS trial team took a pragmatic approach to this problem,
using a definition of late-onset sepsis for the primary outcome that is different from other trials and
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undertaking an independent review of the categorisation of NEC. The difficulties are not underestimated;
nonetheless, the lack of agreed simple practical definitions is a major obstacle to progress and,
in conjunction with regulators, needs urgently to be addressed.
The choice of products for probiotic trials
Research into the developmental biology and pathophysiology underlying neonatal NEC and late-onset
sepsis progresses and ultimately should point the way to the identification of evidence-based interventions
that can be tested in clinical trials to prevent NEC and late-onset sepsis, but that stage has not yet
been reached.
The choice of probiotic product for this trial seemed, when made, to have a sound clinical basis but,
in retrospect, given progress in understanding the pathogenesis of NEC and late-onset sepsis and the
complex biology of the microbiome over the past decade, was perhaps naive.
The conventional route of undertaking large expensive Phase 3 trials only after evidence has been gained
from animal and smaller trials in humans supporting efficacy and safety may not be appropriate for
probiotic interventions. A bacterium having probiotic properties might behave differently in a different
species and its action might vary with the developmental stage. At the very least, however, it would
probably be advisable in the future before embarking on large neonatal probiotic trials to complete more
formal and bigger ‘pilot’ studies using clinical end points; however, this is fraught with difficulties and risks
being misleading. Such studies might be designed to involve increased longitudinal sampling to give an
opportunity to study colonisation and in that way throw increased light on issues of dosage particularly in
relation to feeding and antibiotic use.
What is undoubtedly important is that product quality is monitored and colonisation rates are documented
throughout and not just during the set-up phase of clinical trials.
Randomised controlled trials to evaluate probiotics
We do not consider that efficacy of B. breve BBG-001 to prevent NEC and late-onset sepsis was missed in
the PiPS trial because of the complication of cross-colonisation; nonetheless, cross-colonisation is probably
a feature of all probiotic trials and complicates their interpretation. The problem could be overcome by
adopting a cluster design although even that precaution, in the context of unpredictable patterns of
transfer within the UK neonatal service, might not totally overcome the problem and in addition has major
organisational implications.
The well-designed RCT is the supreme assessment of efficacy since it provides a clean experiment with all
confounders taken into account. To suggest that it might not be the optimal way to evaluate a probiotic
and to suggest that the conclusions from a trial of a probiotic might be less likely to translate into clinical
practice than those of a trial of a stable chemical entity may seem heretical, but these suggestions are
worthy of consideration. We can only speculate, but from what we have found it seems inevitable that if a
probiotic is introduced into routine practice it will be incorporated into the bacteriological environment of
the neonatal unit. We are unaware of any longitudinal studies of the effects of prolonged routine use, if
any, on the microbiome in terms of its diversity and frequency of antibiotic-resistant strains in a population
of babies, but this is critically important. It is indeed possible not only that an intervention that seemingly
shows efficacy in a trial might lose that efficacy over time but equally that an intervention that shows
no evidence of benefit might, over time, promote bacterial diversity and be associated with reduced rates
of NEC and late-onset sepsis. The same may be true whether or not the intervention is safe.
Studying probiotic efficacy and safety outside a randomised controlled trials
It is inconceivable that all of the outstanding questions about choice and combinations of probiotic and
other bioactive interventions can be answered through RCTs.
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The pathogenesis of NEC and of neonatal late-onset sepsis is complex, involving the interplay of the
acquisition of a microbiome that is different from that of the full-term healthy baby, with functionally
immature intestinal and immune systems, and, superimposed upon that, effects of enteral nutrition and
administered medications such as antibiotics and antacids.
There is a strong association between the prolonged use of antibiotics and NEC and it is known that the
provision of maternal breast milk affords some protection. Furthermore, there is accumulating evidence
that the use of evidence-based care bundles may reduce neonatal adverse outcomes including late-onset
sepsis and NEC97,98 and it has also been shown in the UK that, through enthusiastically supported quality
improvement programmes, the use of maternal breast milk may be increased.99 Breast milk itself is a safe
means to provide not only commensal bacteria and bifidogenic oligosaccharides, but also a range of other
factors including lactoferrin and growth factors.
In England, all neonatal units routinely collect a common clinical data set, an anonymised subset of
which is held in the Neonatal Data Analysis Unit at Imperial College London.100 Those data items, the
completeness and accuracy of which are steadily increasing, constitute a kite-marked research data set
(ISB1595) that includes both interventions and outcomes. These have been successfully linked to Hospital
Episode Statistics and have the potential to link to other child health systems, opening up possibilities for
obtaining longer-term outcome data. This rich data source has already been the basis of a number of
important publications and has huge potential for investigating the effects and the interactions of
interventions such as probiotics, prebiotics and other bioactive products that are likely to need testing and
whose effects might change over time. Ensuring the completeness and accuracy and the quality of the
analysis of these ‘routine’ data may yield more knowledge about the true impact of introducing probiotics,
or any other intervention, than the best-designed RCT.
Summary of research recommendations
1. Further streamline training of research competent clinical and NHS R&D staff to ensure that recruitment
is optimised and adherence to trial protocols is not unnecessarily jeopardised by transfer
between hospitals.
2. Standardise objective case definitions for NEC and late-onset sepsis suitable for epidemiological, trial
and regulatory purposes.
3. Consider undertaking pilot trials with clinical outcomes and embedded longitudinal studies of
colonisation before embarking on large Phase 3 trials of probiotics.
4. During probiotic trials, monitor the quality of the intervention and intestinal ‘colonisation’.
5. If designing RCTs of probiotics, consider cluster design to limit the effects of cross-colonisation.
6. If introducing probiotic (or other bioactive) interventions into routine use, set up long-term longitudinal
monitoring of the microbiome and of clinical outcomes in the neonatal population whether or not
prescribed probiotic.
7. Ensure the completeness and accuracy of routine NHS neonatal data so that it reliably forms the basis
for studies of the multiple influences on acquisition of NEC and late-onset sepsis.
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